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FGFR FGF receptor
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FLT 18F-3’-fl uoro-3’ deoxythymidine
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HaP-T1 nitrosamine-induced pancreati c cancer in hamsters
HER2 human epidermal growth factor receptor 2
HIF hypoxia inducible factor
HSPG heparane sulphate proteoglycan
IFP intersti ti al fl uid pressure
IL interleukin
i.p. intraperitoneal
i.v. intravenous
IVM in vivo microscopy, intravital microscopy
K Baker–Wayland factor = 1.3
kDa kilo Dalton
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LMWH low molecular weight heparin
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RT radiotherapy
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TFPI ti ssue factor pathway inhibitor
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TNF tumour necrosis factor
UF unfracti onated heparin
USPIO ultra-small superparamagneti c iron oxide nanoparti cle
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VEGF vascular endothelial growth factor
VEGFR VEGF receptor
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9CHAPTER 1: INTRODUCTION
Malignant diseases are the second most important cause of death worldwide, 
accounti ng for well over 7 million deaths in 2008, which is 12,6% of the annual 
mortality. Within 15 years, due to the growth and aging of the populati on, the global 
burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer 
deaths [1]. Cancer research remains an intense area of investi gati on, and despite 
many eﬀ orts the underlying mechanisms of cancer development, cancer behaviour, 
response or resistance to treatment, metastasis, etc. are not fully elucidated. Current 
treatment opti ons include surgery, chemotherapy, radiati on and immunotherapy, but 
these regimens hold serious disadvantages and aspecifi c side-eﬀ ects. Selecti ve tumour-
targeted delivery of drugs or contrast agents is a promising approach for pati ent-tailored 
therapy. In the following chapters and studies, we highlight some aspects of the role of 
neoangiogenesis in cancer, and of targeti ng the angiogenesis in treatment and imaging.
1.1 HALLMARKS OF CANCER
The development of cancer is dependent on 10 essenti al alterati ons in cell physiology, 
as reported by Hanahan and Weinberg [2,3], dictati ng malignant growth: sustaining 
proliferati ve signaling, evading growth supressors, avoiding immune destructi on, 
enabling replicati ve immortality, tumour-promoti ng infl ammati on, acti vati ng invasion 
and metastasis, inducing angiogenesis, genome instability and mutati on, resisti ng cell 
death, and deregulati ng cellular energeti cs (Fig. 1.1). Each of these novel functi onal 
capabiliti es acquired during tumour development, represents a victory on an anti cancer 
mechanism of the host ti ssue. These apparently normal neighbours (fi broblasts, 
endothelial cells (ECs), pericytes, extracellular matrix (ECM)), play key roles in driving 
tumour growth through paracrine signaling.
In the next paragraphs, we focus on the ability to induce tumoural angiogenesis, and on 
therapeuti c strategies to block angiogenesis in the batt le against cancer.
FIGURE 1.1: Acquired capabiliti es of cancer cells . (Adapted from Hanahan and Weinberg, 2011 [3]).
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1.2 Tumour neovasculature
When neoplasti c cells develop in a human body, without att ack of the host immune 
system, multi plicati on of these cells will start. In this stage, all necessary nutrients and 
oxygen will be delivered by passive diﬀ usion, which is suﬃ  cient for distances up to 100-
200 μm. Aft er reaching a criti cal mass, the formati on of new blood vessels is needed to 
feed the tumour. The relati onship between the vascular system and malignant diseases 
was already observed more than 100 years ago by Goldman et al. [4]. Several decades 
later, Folkman et al. [5] launched the idea to ‘starve’ tumours by blocking angiogenesis 
as tumour growth and metastasis rely on neovasculature.
Growing tumours develop new blood vessels through diﬀ erent endothelial-cell-related 
mechanisms (Fig. 1.2). The fi rst one is budding and sprouti ng using endothelial cells in 
the established vascular network (sprouti ng angiogenesis). Secondly, intussuscepti on 
expands the blood vessel system by invaginati on of the existi ng vascular lumen. Loop 
angiogenesis is described as expansion of translocated vessels by mechanical forces, 
from contracti ng myofi broblasts. A fourth important way to form new blood vessels is 
recruiti ng angioblasti c progenitor cells from the blood stream, a process called postnatal 
vasculogenesis. Also, a similar process with new lymphati c vessels will take place in a 
tumour (lymphangiogenesis) [6].
Tumour-cell-related mechanisms include vascular mimicry (VM), mosaic vessel formati on 
or vessel co-opti on (the incorporati on of cancer cells into an existi ng vessel wall), and 
tumour cell diﬀ erenti ati on into endothelial cells. Tumours with high IFP (intersti ti al fl uid 
pressure) are known to have limited endothelial cell sprouti ng from the host ti ssue, but 
more VM channel formati on [7] leading to a fracti on of tumour vessels which is likely 
to be resistant to anti angiogenic treatment [8]. This type of neoplasti c vasculature is 
described in lung, colon, liver cancers, sarcomas and melanoma and associated with 
poor overall survival in pati ents and metastati c disease [9].
 
FIGURE 1.2: Sprouti ng angiogenesis, vasculogenesis, intussuscepti on, vessel co-opti on, vascular mimicry, and tumour 
cell-to-endothelial cell diﬀ erenti ati on are mechanisms for expanding the tumour vascular network. (Adapted from 
Carmeliet and Jain, 2011 [13]).
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Unlike normal microvasculature, which has a regular and ordered structure, 
tumour vasculature is macroscopically chaoti c, dilated, and tortuous [10,11]. Also 
microscopically, structural disorders are typical in these newly formed vessels. As a 
response to proangiogenic signals (such as vascular endothelial growth factor (VEGF) 
and Angiopoieti n-2 (Ang-2)), pericytes detach, gaps between endothelial cells enlarge, 
and basement membrane remodels [12,13]. Consequently, microvascular functi on is 
abnormal, with an increased vessel leakiness and IFP [14,15]. These alterati ons produce 
spati al and temporal heterogeneity in blood fl ow and perfusion in tumours, leading 
to regional acidosis and hypoxia [16]. The abnormal microenvironment can promote 
tumour progression in various ways. Hypoxic conditi ons render cancer cells more 
malignant by changing the cell metabolism, promoti ng the epithelial-to-mesenchymal 
transiti on, and compromising the functi on of immune cells [17]. Another mechanism is 
the infl uence of the microenvironment on treatment resistance. In the early fi ft ies, Gray 
and his group described the connecti on between low ti ssue oxygenati on and tumour cell 
radioresistance: radiotherapy relies on the formati on of oxygen radicals to kill cancer cells 
eﬀ ecti vely [18]. Moreover, hypoxia inducible factor-1 (HIF-1) is known to upregulate the 
multi drug resistance gene (MDR1) resulti ng in eﬄ  ux of chemotherapeuti cs [19]. Finally, 
due to increased IFP and poor perfusion, a low oncoti c pressure diﬀ erence across the 
tumor microvascular wall with high oncoti c pressure in tumours, delivery of therapeuti c 
agents to neoplasti c cells will be subopti mal [14]. 
Taken together, the abnormal tumour vascular network results in an acid, hypoxic 
microenvironment with high IFP. These conditi ons contribute to tumour growth, 
metastasis and resistance to therapy. Normalizing this pathological environment could 
be an interesti ng strategy in the treatment of cancer.
1.3 Concept of vascular normalizati on
Anti angiogenic therapy was initi ally developed to target tumour blood and nutrient 
supply, and likewise to reduce tumour growth and metastasis by starvati on [4]. 
Preclinical data supported this hypothesis in a mouse colorectal cancer model during 
anti -VEGF therapy [20]. Despite these fi ndings, the reported benefi cial eﬀ ect of anti -
VEGF monotherapy in clinical setti  ng is modest [21], but reveals to be synergisti c in 
combinati on with chemotherapy [22]. 
To explain these fi ndings, Jain proposed the concept of vascular normalizati on for the 
fi rst ti me in 2001 [23] (Fig. 1.3). 
Anti angiogenic therapy could correct both structure and functi on of tumour vessels 
and as a consequence, produce a normalized microvascular environment with bett er 
prognosis and response to treatment. Indeed, several studies in diﬀ erent tumour 
models reported a positi ve eﬀ ect on tumour oxygenati on, an ameliorati on of delivery 
of systemically administered drugs into tumour and a reducti on of cell shedding and 
metastasis [24]. Under physiological circumstances, proangiogenic factors (e.g. VEGF, 
basic fi broblast growth factor (bFGF), Ang-2) are in balance with anti angiogenic factors 
(VEGFR1, thrombospondin-1, Ang-1). In pathological conditi ons, such as cancer or 
infl ammati on, this balance is in favour of proangiogenic molecules: “the angiogenic 
switch”. Therapy with anti angiogenic drugs can transiently correct this imbalance. The 
closure of the “window of normalizati on” relates to the acti vati on of other proangiogenic 
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pathways in the ti ssue. Defi ning the ti ming and dosing of the anti angiogenic therapies in 
pharmacological studies is an essenti al next step.
 
FIGURE 1.3: Proposed role of vessel normalizati on in the response of tumours to anti angiogenic therapy. A: tumour 
vasculature is structurally and functi onally abnormal. It is proposed that anti angiogenic therapies initi ally improve 
both the structure and the functi on of tumour vessels. However, sustained or aggressive anti angiogenic regimens 
may eventually prune away these vessels, resulti ng in a vasculature that is both resistant to further treatment and 
inadequate for the delivery of drugs or oxygen. B: dynamics of vascular normalizati on induced by VEGFR2 blockade. On 
the left  is a two-photon image showing normal blood vessels in skeletal muscle; subsequent images show human colon 
carcinoma vasculature in mice at day 0 and day 3 aft er administrati on of VEGR2-specifi c anti body. C: diagram depicti ng 
the concomitant changes in pericyte (red) and basement membrane (blue) coverage during vascular normalizati on. D: 
these phenotypic changes in the vasculature may refl ect changes in the balance of pro- and anti angiogenic signaling in 
the ti ssue.
(Adapted from Goel et al., 2011 [24]).
1.4 Proangiogenic molecular strategies
The principal angiogenic molecule responsible for vascular abnormaliti es is VEGF-A (also 
known as VEGF). This is produced by tumour cells in response to hypoxia/HIF, ti ssue 
factor (TF), oncogene acti vati on, sex hormones such as estrogens and progesterones, 
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infl ammatory cytokines. VEGF-A may also be derived from tumour-infi ltrati ng myeloid 
cells, pericytes, or released from the extracellular matrix, and acts primarily via VEGFR2 
on endothelial cells. In additi on, VEGF-A sti mulati on of VEGFR2 on pericytes inhibits 
platelet-derived growth factor receptor (PDGFR)-mediated pericyte recruitment 
to endothelial cells, and causes vessel leakage. Placental growth factor (PlGF) may 
contribute to tumour vessel abnormaliti es through interacti on with VEGFR1, and bFGF 
through interacti on with fi broblast growth factor receptor (FGFR) (Fig. 1.4).
Integrins are plasma membrane receptors, upregulated on tumour cells or on acti vated 
endothelial cells, and mediate att achment between cells or the ECM, providing essenti al 
signals for cell migrati on and angiogenesis. Interacti ons between αvβ3 integrin and 
the FGFR and between αvβ5 integrin and VEGFR2 promote bFGF- and VEGF-mediated 
angiogenesis, respecti vely [24].
Another strategy of tumour cells to successfully permeate the ECM is to produce 
proteinases, e.g. heparanase or matrix metalloproteinase (MMP), with a degradati on 
of the rigid ECM, allowing ti ssue invasion of both ECs and tumour cells, and metastasis. 
Tumour-derived growth factors bind to heparane sulphate proteoglycans (HSPGs) that 
are present in both the ECs and the ECM. Binding of the receptors on the endothelial 
wall results in proliferati on and migrati on of ECs, leading to characteristi c vessel 
abnormaliti es. HSPGs play also a crucial role in stabilizing tumour cells in the wall of 
vessels in VM or mosaic vessel formati on [7].
 
FIGURE 1.4: Factors inhibiti ng the vascular normalizati on phenotype in tumours. This schemati c depicts a tumour cell 
(yellow), endothelial cell (red), surrounding pericytes (green), and the extracellular matrix. (Adapted from Goel et al., 
2011 [24]).
All these proangiogenic strategies lead to an abnormal tumour neovasculature and 
an aberrant microenvironment, and contribute greatly to the malignant phenotype of
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tumours. In this way, strategies to improve (or normalize) vessel structure and functi on 
through anti angiogenic therapies, may delay progression and improve delivery and 
eﬃ  cacy of cytotoxic therapies.
1.5 Anti angiogenic therapy
1.5.1 Directly targeti ng VEGF pathways
VEGF-mediated signaling is important in tumour biology through its eﬀ ect on 
angiogenesis and vascular permeability, but also on tumorigenesis [25] (Fig. 1.5). VEGF-
targeted therapy is currently used for the treatment of many cancers. Dickson et al. 
[26] described aft er treatment with VEGF anti bodies (e.g. bevacizumab) in mice bearing 
human neuroblastoma xenograft s a decreased microvessel density (MVD), vessel 
length, diameter, and tortuosity. Also, an increased pericyte coverage index (PCI) was 
seen aft er therapy in these animals, which depicts maturati on of vessels. Together with 
the structural changes in tumoral microvessels a normalized functi on was observed, 
with reducti on of permeability, decrease of tumour IFP and augmented perfusion, 
leading to improved delivery of chemotherapeuti c agents and tumour growth delay. 
Similar fi ndings were reported by Gorski et al. [27], with synergisti c eﬀ ects of combining 
anti -VEGF treatment and radiotherapy. In clinical trials, indeed, bevacizumab has 
led to improved overall survival, or progression-free survival in combinati on with 
chemotherapy in well-defi ned groups of cancer pati ents [28,29].
                 
FIGURE 1.5: VEGF-functi ons in tumours. VEGF that is secreted by tumour and stromal cells, including macrophages, 
endothelial cells and fi broblasts, has multi ple functi ons in the tumour environment, which involve the ability of VEGF 
to interact with VEGF-receptors that are expressed on diﬀ erent cell types. VEGF functi ons as a primary sti mulus for 
angiogenesis, which is a process that involves the ability of VEGF-receptors to sti mulate signaling pathways that induce 
the proliferati on and the migrati on of endothelial cells, and the ability of these cells to degrade and to remodel the 
extracellular matrix. These processes culminate in sprouti ng angiogenesis, and the formati on of new blood vessels. 
VEGF can also increase vascular permeability, which results in the depositi on of a provisional fi brin matrix that triggers 
the formati on of desmoplasti c stoma. By contrast, VEGF secreted by tumour cells functi ons in an autocrine manner 
and promotes dediﬀ erenti ati on and an epithelial-mesenchymal transiti on phenotype, with a consequent enhancement 
of tumour invasion and survival, and it can facilitate the functi on of cancer stem cells. VEGF can also functi on as a 
chemoatt ractant to recruit regulatory T-cells that inhibit an anti tumour immune response. Tumour fi broblasts also 
secrete VEGF. (Adaptad from Goel and Mercurio, 2013 [25]).
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VEGFR2 is expressed at high levels on tumour vasculature and is an interesti ng target to 
block VEGF-VEGFR2 signaling with anti bodies. Tong et al. [15] used intravital microscopy 
in a mouse dorsal skinfold chamber model showing that within 3 days of therapy with 
VEGFR2-anti bodies, a reduced MVD and diameter was seen, and an increased PCI in 
tumour vessels. Vessel permeability and IFP decreased, and intersti ti al penetrati on 
improved [15].
Similar fi ndings were observed with receptor tyrosine kinase inhibitors (TKI); e.g. 
cediranib, a TKI of VEGFR1, VEGFR2, and VEGFR3, had a direct therapeuti c eﬀ ect in a 
mouse glioblastoma multi forme model with reducti on of IFP and intracranial oedema 
due to vessel normalizati on, and consequently an extended survival [30]. Moreover, 
an increased overall survival was reported in a clinical trial comparing sorafenib with 
placebo in pati ents with hepatocellular carcinoma [31].
Another member of the VEGF family is PlGF, which has an important role in pathological 
conditi ons, such as cancer, infl ammati on, and cirrhosis, but not in physiological 
conditi ons. The group of Carmeliet [32] showed that anti -PlGF therapy results in tumour 
growth reducti on, more mature vessels, a drop of tumour hypoxia and enhanced eﬀ ect 
of cytotoxic treatments. The concept of vascular normalizati on aft er anti -PlGF treatment 
was also proven in mice with cirrhoti c livers [33] and revealed to have bett er safety 
profi les than e.g. receptor TKI.
1.5.2 Indirectly targeti ng VEGF or other pathways
1.5.2.1 INTEGRIN ANTAGONISTS
The integrins are a group of evoluti onary conserved heterodimeric cell surface receptors 
which are essenti al in cell-cell and cell-matrix interacti ons [34]. Some subtypes, such as 
αvβ3, αvβ5, and α5β1, are highly overexpressed on cancer cells and play important roles in 
mediati ng tumour angiogenesis. Other subtypes, αvβ6 and α6β4, have pivotal functi ons 
in cell migrati on, and hence metastasis [34] (Fig. 1.6). These interesti ng capaciti es of 
certain integrins, and the high level of expression on several tumour types, makes them 
ideal candidates for targeted therapy and imaging studies.
A potenti al target is αvβ3 integrin, which is overexpressed on some tumour cell types 
(e.g. lung cancer, ovarian cancer, breast cancer, glioblastoma multi forme [35]) and also 
selecti vely expressed on acti vated EC during migrati on through the basement membrane 
in the angiogenic process, such as during tumour neoangiogenesis [36,37]. This protein 
is not upregulated on quiescent EC [38]. Angiogenesis induced by bFGF requires the 
functi on of integrin αvβ3, whereas angiogenesis induced by VEGF requires the functi on 
of integrin αvβ5 [39]. As these integrins have key functi ons in tumoural metabolism, they 
also hold promise in tumour-targeted imaging to monitor therapy.
Cilengiti de, a cyclic pentapepti de mimicking the Arg-Gly-Asp (RGD) binding site, was 
identi fi ed as a potent αv integrin antagonist selecti vely targeti ng ECM components of 
αvβ3 and αvβ5 integrins. It is known to block bFGF- and VEGF-mediated angiogenesis, 
with a resulti ng normalizati on of the tumour microenvironment [40]. In preclinical 
models, cilengiti de was synergisti c with radioimmunotherapy in breast cancer and 
orthotopic brain tumor models [41,42]. In clinical phase III studies, however, this 
promising molecule sti ll has to prove its eﬃ  cacy in diﬀ erent cancer types [43].
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FIGURE 1.6: αv integrins expressed on multi ple cell types contribute to angiogenesis and tumour progression. Sprouti ng 
endothelial cells express a unique profi le of integrins that can be targeted to suppress vascular proliferati on. Tumour 
cells change integrin expression profi les to enhance their ability to migrate, invade, metastasize, and survive in hosti le 
environments. Integrins signaling in fi brobla sts directs synthesis of extracellular matrix proteins and growth factors 
that fl ood the tumor stroma. Proteolyti c degradati on of ECM proteins creates fragments that can bind to and inhibit 
the functi on of integrins expressed by angiogenic endothelial cells. In summary, integrin expression profi les of normal 
cells are disti nct from those within remodeling ti ssue. Because integrin signaling pathways can infl uence the behavior of 
multi ple cell types involved in angiogenesis and cancer, selecti ve targeti ng of integrin-mediated adhesion and signaling 
represents an att racti ve therapeuti c strategy. (Adapted from Weis and Cheresh, 2011 [36]).
1.5.2.2 HEPARINS AND LMWHS
Diﬀ erent clinical studies have suggested that, independently from its eﬀ ect on the 
incidence of venous thromboembolic events (VTEs), heparin therapy might improve 
survival in cancer pati ents [44,45] with bett er results for low molecular weight heparin 
(LMWH) than unfracti onated heparin (UFH) [46]. LMWH acts through anti -factor Xa and 
anti -factor IIa acti vity (Fig. 1.7), and releases ti ssue factor pathway inhibitor (TFPI). Major 
side eﬀ ects, such as bleeding, were stati sti cally not signifi cantly diﬀ erent in placebo 
recipients or LMWH-treated pati ents [47]. The potenti al anti cancer mechanisms of 
LMWH administrati on include coagulati on-dependent and coagulati on-independent 
pathways. Eﬀ ects on the formati on of cancer metastasis (tumour cell heparanase), cancer 
cell adhesion and invasion (cell surface selecti n-mediated), immune response, and 
angiogenesis (heparin-binding growth factors, TFPI) [48-52] are reported, independently 
of the anti coagulant eﬀ ect of LMWH [53,54]. Some anti angiogenic eﬀ ects of LMWH 
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rely on the eﬀ ect on heparin-
binding growth factors such as 
VEGF and bFGF. These growth 
factors bind to HSPGs that are 
present in both the ECs and the 
ECM. Binding of the receptors 
on the endothelial wall results 
in proliferati on and migrati on 
of ECs. Soluble heparins have 
been shown to compete with 
angiogenic growth factors for 
ECM binding sites, and UFH 
therapy increases the plasma 
levels of certain growth factors 
[55]. In contrast to UFH, LMWHs 
inhibit binding of heparin-
binding growth factors to their 
endothelial receptors, with 
larger fragments inhibiti ng the 
acti vity of VEGF, whereas smaller 
fragments reduce bFGF acti vity 
[56-58]. Similarly, in an in vivo 
assay aft er intraperitoneal VEGF 
administrati on, angiogenesis 
was suppressed by a 5-kDa but not by a 2.5- or 16.4-kDa heparin fracti on [59].
LMWHs excert their anti angiogenic eﬀ ect not only through inhibiti on of growth factors, 
but also through inhibiti on of heparanase and MMP [60,61]. These enzymes are 
overexpressed in tumours and are responsible for degradati on of ECM, the release of 
angiogenic factors from the tumour microenvironment and are related to progression 
of cancer and metastasis [62]. They shed cadherins, important in tumour cell adhesion, 
and potenti ate vascular leakage through acti vati on of chemokines [63]. In this way, 
LMWHs blocking heparanase and MMP, normalize the ECM and vascular permeability.
Another documented pathway in anti angiogenesis, involves the anti coagulant property 
of LMWH to induce a release of TFPI from the vascular endothelium, as the inhibitory 
eﬀ ect of ti nzaparin is blocked by a monocolonal TFPI anti body [64]. Tissue factor (TF) is 
abundantly expressed in many tumour cell types and correlates with hypercoagulability, 
increased angiogenesis and higher tumor grades. TF upregulati on in endothelial cells, 
which do not normally express TF, may be due to VEGF under tumoural conditi ons [65].
1.5.3 Combining anti angiogenics
Many tumours are intrinsically not sensiti ve for anti -angiogenic therapy or develop 
secondary resistance, by upregulati on of other proangiogenic pathways. An answer to 
using anti angiogenics lies in the combinati on of compounds that aﬀ ect diﬀ erent aspects 
of angiogenesis, if toxicity can be reduced [66].
In the preclinical setti  ng, controlling primary tumour growth can be more eﬀ ecti ve when 
FIGURE 1.7: The coagulati on cascade.
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a VEGFR-2 tyrosine kinase inhibitor is combined with a PDGFR tyrosine kinase inhibitor 
[67]. Similar fi ndings were reported combining bevacizumab and cediranib, compared 
to each product alone [68]. Currently, several clinical phase I and II trials are ungoing 
to confi rm a synergisti c eﬀ ect of anti angiogenic strategies and to evaluate toxicity [66].
Recently, eﬀ orts were directed to develop a LMWH derivati ve (targeti ng VEGF) undergoing 
chemical conjugati on with cyclic Arg-Gly-Asp (RGD)-containing small pepti des targeti ng 
αvβ3 integrin. Indeed, this agent has higher anti angiogenic eﬃ  ciency than that of the 
LMWH derivati ve alone in in vitro experimental models, with signifi cantly decreased 
MVD and tumour volume in in vivo models [69]. No additi onal eﬀ ects on normalizati on 
of vessel functi on were examined.
1.6 Biomarkers for anti -angiogenic therapy
To identi fy pati ents who benefi t from anti -angiogenic therapies, and to overcome 
resistance to anti -angiogenic strategies, which lead to the risk of developing a more 
malignant tumour phenotype, it is crucial to defi ne biomarkers of tumour response in 
an early phase of treatment. These predicti ve markers could be circulati ng factors (VEGF, 
PlGF, soluble VEGFRs) [24], ti ssue factors in biopsies, single nucleoti de polymorphisms 
(SNPs) in DNA of pati ents [70], or imaging parameters.
Easily accessible structural imaging modaliti es can oﬀ er images with good spati al 
resoluti on in a non-invasive way, but they share the limitati on of not being able to 
detect lesions unti l the structural changes in the ti ssue (e.g. tumor growth or shrinkage) 
are large enough to be detected by these imaging technologies [71] which means crucial 
ti me is lost. Recent advances in molecular and functi onal imaging could be a soluti on.
Since the introducti on of agents targeti ng tumour angiogenesis, increasing eﬀ orts 
have been invested in functi onal imaging of the neoplasti c vascular bed. Most imaging 
modaliti es (PET, CT, ultrasonography, MRI) use contrast agents to improve visualizati on 
of tumour behaviour. Importantly, the earliest sign of response to anti -angiogenic 
therapy is microvessel normalizati on and a known hallmark of this process is a decrease 
in microvascular permeability. We previously showed that dynamic contrast enhanced 
(DCE)-MRI incorporati ng mathemati cal modelling allows to quanti fy early changes in 
microvessel permeability (Ktrans) as well as tumour perfusion [72,73]. In studies with 
anti angiogenesis and anti vascular agents [74] imaging biomarkers from DCE-MRI 
or perfusion CT (pCT), correlated with therapeuti c drug dose [75-78] and eﬃ  cacy, or 
pati ent survival [79,80]. Similar fi ndings are also seen with chemotherapy [81], and 
radiotherapy [82]. 
To develop a predictor of an individual pati ent’s progression-free and overall survival, a 
new biomarker was described by the group of Jain: the “vascular normalizati on index” 
(VNI), quanti fying the fall in Ktrans, the decrease of tumour microvessel volume, and the 
rise in plasma level of collagen IV (which is a marker of vascular basement membrane 
thinning) using multi variable Cox regression analyses of changes in these three 
parameters [83]. The VNI proved to be a good predictor for survival in cediranib-treated 
glioblastoma pati ents.
Contrast-enhanced ultrasonography (CE-US) is another functi onal imaging modality 
which is currently under investi gati on. Semiquanti tati ve data analysis is possible and a 
064871 thesis 16x24 niet split.indd   18 2/09/14   07:10
19
reducti on in tumor vascularity parameters, measured by CE-US, can predict response to 
therapy in liver, renal, and gastrointesti nal stromal tumors [84-87].
Finally, isotope imaging with PET is a common tool in oncology practi ce. The basic 
principle of this imaging modality is that it uses the characteristi cs of tumours to 
incorporate specifi c radioacti ve nuclides which are combined with other elements to 
form chemical compounds. These contrast agents provide informati on about tumour 
cell metabolism (FDG), tumour hypoxia, or tumour cell proliferati on (FLT), and isotope 
imaging will record radiati on emitti  ng from within the body rather than radiati on that is 
generated by external sources. For instance, 18F-3’-fl uoro-3’deoxythymidine (FLT)-PET is 
incorporated by proliferati ng cells in the pyrimidine salvage pathway during the S-phase. 
The tracer is then phosphorylated by thymidine kinase 1, aft er which it accumulates in 
the cells [88]. Several clinical studies have aimed to use FLT-PET to monitor the response 
to anti proliferati ve therapy. In breast cancer, FLT-PET enabled early response predicti on, 
i.e. aft er one course of chemotherapy [89,90].
Whereas functi onal imaging depicts indirect signs of tumour response, molecular
imaging has the advantage to give informati on about tumour specifi c details of 
microvasculature using probes directed against receptors expressed on the proliferati ng 
EC surface, which are detectable at nanomolar concentrati ons [91]. This allows not only 
early monitoring of therapy, but also the development of contrast agents that even 
could deliver drugs to the targeted tumour (vessel) receptors [92].
MRI is hereby an interesti ng tool, but this technique is limited by the low sensiti vity 
to visualize these low concentrated epitopes. Therefore, eﬀ orts have been made to 
combine target-specifi c molecules with a large (super)paramagneti c payload. Several 
authors have used RGD-coupled liposomes containing Gd-DTPA for visualizati on of 
integrins in tumour angiogenesis [93,94], or RGD-labeled ultra-small superparamagneti c 
iron oxide nanoparti cles (USPIO) [95-97].
On the other hand, molecular imaging using PET has a superior sensiti vity, even at 
very low contrast agent concentrati ons. Radiolabeled VEGF, or other mediators of 
angiogenesis, can predict response to anti -VEGF treatment [98]. Radioiodinated RGD 
pepti des reveal integrin receptor-specifi c tumour uptake [91]. PET scanning aft er 
administrati on of radiolabeled trastuzumab allowed identi fi cati on and quanti fi cati on of 
expression of HER2-positi ve tumors in pati ents with metastati c breast cancer [99].
Recently, new promising technologies with sophisti cated opti cal probes have been 
developed that target with biological processes on a molecular level aft er being 
exogenously delivered. The design of such probes involves the att achment of a 
fl uorophore to a targeti ng moiety, such as a pepti de, an anti body or a fragment of 
an anti body, small molecules, and nanoparti cles. Most of these fl uorescent probes 
are completi ng preclinical validati on in mouse models [100-104]. The advancements 
in nanoparti cle fl uorescent probe imaging will benefi t open and endoscopic cancer 
surgery, for visualizati on of resecti on margins, jump metastases and lymph node 
involvement (Fig. 1.8) [105-107].
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FIGURE 1.8: (A) In vivo near infra red (NIR) fl uorescence imaging of tumour-bearing mice aft er tail vein injecti on of 
cyclicRGD NIR quantum dot bioconjugates (a non-injected mouse is used as grey control); (B) NIR imaging-guided surgery 
performed 48h aft er injecti on; and (C) the solid tumour precisely removed. Adapted from Li et al., 2012 [102]. 
Taken together, identi fi cati on of a validated, non-invasive biomarker is a key challenge 
for the future, to tailor anti tumour strategies for each cancer pati ent, preventi ng 
unnecessary treatments, reducing the risk of toxicity and resistance, and deminishing 
health care costs. This important step can produce new insights in the mechanisms of 
anti angiogenic therapies.
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Current cancer treatment opti ons include surgery, chemotherapy, radiati on and 
immunotherapy, but these regimens are known to evoke diﬀ erent disadvantages and 
aspecifi c side-eﬀ ects. Improving the treatment specifi city, leading to a pati ent-tailored 
approach, is an essenti al next step in treati ng cancer eﬀ ecti vely. By ti mely disconti nuati on 
of inacti ve regimens, tumour resistance to therapy is prevented, quality of life of the 
pati ent is maintained by circumventi ng treatment toxicity, and unnecessary costs are 
avoided. Every single detail in the underlying mechanisms of cancer development, 
cancer behaviour, response or resistance to therapy, metastasis, can be a potenti al 
treatment target. In this complicated network, we focus on tumour neoangiogenesis as 
a target for therapy.
Overexpression of proangiogenic factors leads to formati on of tumour vasculature which 
is chaoti c, dilated, and tortuous [1]. In this heterogenous network, other structural 
changes take place, e.g. pericytes detach, gaps between endothelial cells enlarge, 
and basement membrane remodels [2,3]. Consequently, microvascular functi on is 
abnormal, with an increased vessel leakiness and IFP [4,5]. These alterati ons produce 
spati ally and temporally heterogeneity in blood fl ow and perfusion in tumours, leading 
to regional acidosis and hypoxia [6], rendering the tumour phenotype more malignant. 
At last, due to increased IFP and poor perfusion, systemically administered drugs fail to 
enter tumour regions [3].
In chapter 3.1, we examine the vascular normalizati on eﬀ ect of the LMWH nadroparin 
on tumour angiogenesis using a dorsal skinfold window chamber model in the 
Syrian golden hamster. Most of the experimental data on the anti cancer eﬀ ects of 
heparins were generated by cell culture experiments. In vivo microscopy (IVM) allows 
longitudinal non-invasive observati on of tumour angiogenesis in the living animal, with 
quanti fi cati on of microvessel density, red blood cell velocity, microvascular diameter 
and volumetric blood fl ow over ti me. Histological data, concerning microvessel density, 
pericyte coverage index and fractal dimension, help to evaluate the degree of vascular 
normalizati on aft er treatment. In this study, pancreati c carcinoma and amelanoti c 
melanoma is studied in a hamster model. Using a human colorectal cell line, is the 
next logical step, which leads to the study described in chapter 3.2. The aim of the 
this experiment is to study the eﬀ ects of the LMWH nadroparin and enoxaparin on 
colorectal angiogenesis in a mouse xenograft  dorsal window chamber model using IVM 
studies and immunohistochemistry. Ulti mately, these fi ndings can help elucidate the 
behaviour of the tumour microenvironment during anti angiogenic strategies in humans.
To identi fy pati ents who benefi t from certain anti angiogenic therapies, and to overcome 
resistance, which leads to development a more malignant tumour phenotype, it is 
crucial to defi ne biomarkers of tumour response in an early phase of treatment. These 
predicti ve markers could be imaging parameters.
Historically, non-invasive structural imaging modaliti es were used to evaluate tumour 
response to treatment with good spati al resoluti on (e.g. CT, MRI), but they assess only 
morphological, and not functi onal properti es of the neoplasti c ti ssue [7]. In chapter 4.1 
we give an overview of recent advances in molecular and functi onal imaging modaliti es, 
with some promising preclinical developments. Since the introducti on of agents targeti ng 
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tumour angiogenesis, increasing eﬀ orts have been invested in functi onal imaging of 
the neoplasti c vascular bed. One of the earliest signs of response to anti angiogenic 
treatment, with vascular normalizati on, is a decrease of vascular permeability. Dynamic 
contrast enhanced (DCE) magneti c resonance imaging allows to quanti fy these early 
changes in microvessel permeability as well as tumour perfusion [8,9]. Although of 
interest, these parameters remain indirect esti mators of tumour angiogenesis. A direct 
method of early iconographic evaluati on of tumour response requires probes directed 
against tumour-specifi c moieti es expressed on the proliferati ng endothelial cell (EC) 
surface. A potenti al target is αvβ3 integrin, which we studied in chapter 4.2, with a 
novel αvβ3 integrin directed molecular MRI tracer (P1227) as a tool to visualize tumour 
angiogenesis in a colorectal xenograft  mouse model. To prove specifi city of the tracer, we 
used cilengiti de, an integrin αvβ3 inhibitor, before imaging with P1227. The identi fi cati on 
of tumour receptors through imaging allows not only the non-invasive measurement 
of early response to treatment, but can be a tool to develop further tumour receptor-
specifi c delivery of drugs. 
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CHAPTER 3: Vascular normalizati on aft er LMWH-
treatment in cancer
Chapter 3.1: The low-molecular-weight heparin, nadroparin, inhibits tumour 
angiogenesis in a rodent dorsal skinfold chamber model
Debergh I, Van Damme N, Patt yn P, Peeters M, Ceelen W. The low-molecular-weight 
heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber 
model. Br J Cancer. 2010; 5 (102): 837-843.
3.1.1 Abstract
Background:
Recently, low-molecular-weight heparins (LMWHs) were found to confer a survival 
advantage in cancer pati ents. The mechanism underlying this observati on is unclear, 
but may involve inhibiti on of tumour angiogenesis. We aimed to examine the eﬀ ects of 
nadroparin on tumour angiogenesis using a dorsal skinfold window chamber model in 
the Syrian hamster.
Methods:
AMel-3 and HAP-T1 tumours were grown in donor animals and fragments implanted in 
the window chambers. Animals (N=46) were treated with 200IU of nadroparin or saline 
for 10 days. Repeated intravital fl uorescence microscopy was performed to calculate 
functi onal microcirculatory parameters: number (N) and length (L) of microvessels, 
vascular area fracti on (AF), and red blood cell velocity (V). Microvessel density (MVD), 
fractal dimension, and pericyte coverage were assessed histologically.
Results:
Acti ve angiogenesis was observed in control animals, resulti ng in a signifi cant increase in 
N, L, and AF. In nadroparin-treated animals, however, N and L did not increase whereas 
AF decreased signifi cantly. Both groups showed an initi al increase in V, but nadroparin 
treatment resulted in an earlier decrease in red blood cell velocity over ti me. Compared 
with control animals, nadroparin-treated animals showed a signifi cantly lower MVD and 
fractal dimension but signifi cantly higher pericyte coverage index (PCI).
Conclusions:
Taken together, these results suggest that the LMWH nadroparin inhibits tumour 
angiogenesis and results in microvessel normalisati on.
3.1.2 Introducti on
Cancer pati ents are at risk of venous thromboembolic events (VTEs) induced by the 
hypercoagulable state associated with malignancy (Mousa, 2004). There is therefore a 
clear rati onale for prophylacti c administrati on of unfracti onated heparin (UFH) or low-
molecular-weight heparin (LMWH) in these pati ents (Carrier and Agnes, 2009).
Recent clinical studies have suggested that, independent from its eﬀ ect on the incidence 
of VTE, heparin therapy might alter survival in cancer pati ents (Kakkar et al, 2004; Klerk 
et al, 2005).
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The potenti al anti cancer mechanisms of LMWH administrati on remain incompletely 
understood. Suggested targets include the formati on of cancer metastasis, cancer cell 
adhesion and invasion, immune response, and angiogenesis (Smorenburg and Van 
Noorden, 2001; Niers et al, 2007; Zacharski and Lee, 2008). Angiogenesis is a criti cal 
process in survival, growth, and metastasis of a malignant tumour, and is regulated by 
a number of heparin-binding growth factors such as vascular endothelial growth factor 
(VEGF) and basic fi broblast growth factor (bFGF). These growth factors bind to heparane 
sulphate proteoglycans (HSPGs) that are present in both the endothelial cells (ECs) and 
the extracellular matrix (ECM). Binding of the receptors on the endothelial wall results in 
proliferati on and migrati on of ECs. Soluble heparins have been shown to compete with 
angiogenic growth factors for ECM binding sites, and UFH therapy increases the plasma 
levels of certain growth factors (Folkman et al, 1989). In contrast to UFH, LMWHs inhibit 
binding of heparin-binding growth factors to their endothelial receptors, an eﬀ ect that 
depends on the molecule’s number of saccharide units (Norrby, 1993; Norrby and 
Ostergaard, 1996). Fragments of <18 saccharides inhibit the acti vity of VEGF, whereas 
fragments smaller than 10 saccharide units reduce bFGF acti vity (Soker et al, 1994). 
Similarly, in an in vivo assay aft er intraperitoneal VEGF administrati on, angiogenesis 
was suppressed by a 5-kDa but not by a 2.5- or 16.4-kDa heparin fracti on (Norrby and 
Ostergaard, 1997).
Most of the experimental data on the anti cancer eﬀ ects of heparins were generated 
by cell culture experiments. In vivo microscopy (IVM) allows longitudinal noninvasive 
observati on of tumour angiogenesis in the living animal. In this study we studied the 
eﬀ ects of the LMWH nadroparin on tumour-associated angiogenesis, using a dorsal 
skinfold window chamber model in the Syrian golden hamster.
3.1.3 Methods
The experimental protocol was approved by the animal experimental ethical committ ee 
of the Ghent University, Ghent, Belgium. 
Animals and tumour model
Male syrian gold hamsters (Harlan, Horst, The Netherlands) weighing 80–100g were 
housed separately in plasti c cages with free access to tap water and standard pellet 
food.
AMel-3 (Fortner’s amelanoti c hamster melanoma; 50% of the animals) or HaP-T1 
(nitrosamine-induced pancreati c cancer in hamsters; 50% of the animals) cancer cell 
lines were cultured and 1 million cells suspended in 0.1ml of saline were injected 
subcutaneously in the proximal hind leg of donor hamsters. When tumours reached 
a size of 10mm3 (usually aft er 2–3 weeks), four tumour fragments (±0.5–1mm2) were 
implanted in the window chamber of acceptor animals at 24h aft er dorsal skinfold 
window chamber implantati on.
Dorsal skinfold window chamber implantati on
Hamsters were anaestheti sed with intraperitoneal injecti on of ketamine (Ketalar, Pfi zer, 
Elsene, Belgium) and xylazin (Rompun, Bayer, Diegem, Belgium) and placed on a heati ng 
pad. The procedure is described in detail by Endrich et al (1980) and Menger et al (2002). 
064871 thesis 16x24 niet split.indd   34 2/09/14   07:10
35
In brief, a ti tanium frame is surgically fi xed onto a 
dorsal skinfold of the animal (Figure 3.1). On one 
side of the skinfold, a circular area of dermis and 
subcuti s is surgically removed (15mm diameter) 
and covered by a circular cover glass. Animal 
were housed separately and were allowed to 
recover for 24h from surgery and anaesthesia 
before tumour fragment implantati on. Window 
chambers were inspected daily for the presence 
of air bubbles, infl ammati on, infecti on, or 
vascular thrombosis.
Experimental therapy
Animals (N=23 per group) were treated with 
daily subcutaneous injecti ons of either 0.07ml 
of saline or 200IU aXa of nadroparin (Fraxiparine, GSK, Genval, Belgium) dissolved in 
0.07ml of saline. Injecti ons started the day before tumour implantati on.
Intravital microscopy 
In vivo fl uorescence microscopy was performed on days 0 (day of tumour implantati on), 
3, 6, and 9. Unconscious animals (ketamine/xylazin anaesthesia) received an i.v. bolus 
of 0.1ml of fl uorescein isothiocyanate (FITC)–labelled dextran (20mgml–1) (Sigma-
Aldrich NV, Bornem, Belgium) and were placed on the stage of a modifi ed Olympus 
BX51WI microscope (Olympus NV, Aartselaar, Belgium). Fluorescence microscopy 
was performed using an HBO 50W mercury lamp (Osram, Zaventem, Belgium) and a 
FITC fi lter set (excitati on fi lter 460–490nm) for detecti ng epifl uorescent intravascular 
plasma. Stati c and dynamic images of the microcirculati on were obtained in four 
diﬀ erent regions in each chamber. Digital images were captured real ti me on the hard 
disc of a computer using a high sensiti vity digital camera (model C8484-05, Hamamatsu 
Photonics, Hamamatsu, Japan). Quanti tati ve microcirculatory analysis was performed 
using a soft ware package (CapImage, H Zeintl Engineering, Heidelberg, Germany). The 
following parameters were calculated: microvessel length per area (LA; cm–2), number 
of microvessels per high-power fi eld (NA; n/HPF × 20), vascular area fracti on (AF; %), 
and microvessel diameter (D; μm). In additi on, centreline red blood cell velocity (V;
mm s–1) was measured by analysing 10 microvessels per region of interest, randomly 
chosen among those that crossed a verti cal line drawn over the centre of the computer 
screen, as described by Laschke et al (2005). Volumetric blood fl ow (VQ; pl s–1) was 
calculated from V and D as VQ=π × (D/2)2 × V/K, in which K (=1.3) represents the Baker–
Wayland factor (Baker and Wayland, 1974), and considers the parabolic velocity profi le 
of blood in microvessels. Functi onal capillary density was not calculated as angiogenic 
sprouts and buds contain red blood cells without a measurable perfusion and therefore 
this parameter does not accurately refl ect tumour angiogenesis (Torres et al, 1995).
On day 9 aft er implantati on of the tumour fragments, animals were killed and the ti ssue 
inside the observati on chambers was excised for histology. Tissue fragments were fi xed 
 
 
FIGURE 3.1 Dorsal skinfold window chamber
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in 10% formalin, embedded in paraﬃ  n, and 4μm thick secti ons were cut and mounted 
for immunohistochemistry.
Immunohistochemistry
Factor VIII (von Willebrand factor, FVIII) immunostaining was used to visualise tumour 
microvessels and calculate microvessel density (MVD), whereas α-smooth muscle acti n 
(αSMA) was used to identi fy pericytes and calculate the pericyte coverage index (PCI) 
as a measure of microvessel maturati on. Serial ti ssue secti ons were deparaﬃ  nised 
in xylene, hydrated by serial immersion in ethanol, and subsequently incubated in 
Proteinase K (Dako, Heverlee, Belgium) for anti gen retrieval. Endogenous peroxidase 
acti vity was blocked with 3% H2O2 in methanol. Slides were washed in Tris-buﬀ ered 
saline (TBS)–Tween and treated with UltraSens Block RTU (ImmunoLogic, Duiven, The
Netherlands) to inhibit nonspecifi c anti body binding. Secti ons were incubated with 
mouse monoclonal anti bodies against FVIII (Dako) or αSMA (Abcam, Cambridge, UK) 
at room temperature for 1h, rinsed in TBS–Tween, and incubated with secondary 
anti bodies (UltraSens Bioti nylated Goat Anti -polyvalent RTU; ImmunoLogic) followed 
by streptavidin peroxidase (UltraSens Streptavidin Peroxidase RTU; ImmunoLogic) 
for 10min each. Visualisati on of the immunoprecipitate was performed by adding 
3,3’-diaminobenzidine (Biogenex, San Ramon, CA, USA) and counterstaining with 
haematoxylin. Positi ve and negati ve controls were processed simultaneously.
Serial FVIII and αSMA-stained secti ons of dorsal skinfold ti ssue were enti rely scanned for 
tumour regions (magnifi cati on × 20) and digiti sed. Microvessel density was calculated 
by digital image analysis using the NIH ImageJ soft ware (version 1.39s, available from 
htt p://rsb.info.nih.gov/ij). Using the threshold colour plugin, FVIII- and αSMA-positi ve 
cells were isolated from background staining and the resulti ng images converted to 
binary. Microvessel density was calculated using the rati o of black pixels over the total 
number of pixels in the binary image, whereas the PCI was calculated as the rati o of 
αSMA-positi ve pixels vs FVIII-positi ve pixels. The fractal dimension of the microvessel 
bed was calculated using the ImageJ FracLac plugin. The fractal dimension is a rati onal 
number between 1 and 2 (the dimensions of a line and plane, respecti vely), and has 
been shown to correlate with the degree of branching, tortuosity, and irregularity of the 
tumour-associated microvascular network (Dey, 2005).
Stati sti cal analysis
Data are expressed as mean±s.d. or median (interquarti le range). Diﬀ erences were 
analysed using Student’s t-test or Mann–Whitney rank-sum test where appropriate. 
Results were considered stati sti cally signifi cant when the probability of a type I error 
was ≤5%. Stati sti cal analysis was performed with SigmaStat 11.0 (Systat Soft ware, 
Richmond, CA, USA). 
3.1.4 Results
All animals (N=46) developed 2–4 macroscopically visible tumours in the observati on 
window, indicati ng appropriate angiogenesis and viability (Figure 3.2). As both the 
dynamic in vivo microscopic results and histology parameters with the excepti on of the 
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PCI did not diﬀ er between the HaP-T1 cell line and the AMel-3 cell line (data not shown), 
stati sti cal analyses were performed on the combined group. Five animals were excluded 
on the fi rst day of observati on because of insuﬃ  cient opti cal quality of the window 
chamber. In all other animals (N=41), the skinfold chamber provided excellent image 
quality and resoluti on over the durati on of the experiment (9 days). 
FIGURE 3.2 Representati ve tumour growth and angiogenesis observed for 9 days in a control animal (A–D) and a 
nadroparin-treated animal (E–H). The diﬀ erence in microvessel density is clearly visible, as is the higher number of 
neovascular buds and sprouts in the control animal (image D). Scale bar=100 μm.
Eﬀ ects of nadroparin on tumour-induced angiogenesis
The microvascular parameters derived from in vivo microscopic observati ons are 
summarised in Figure 3.3 and Table 3.1. In control animals (N=20), the number 
of microvessels and the vascular area fracti on increased signifi cantly whereas a 
nonsignifi cant increase in vessel length was observed. In nadroparin-treated animals 
(N=21), however, vessel length and number of microvessels did not change signifi cantly 
over ti me whereas a signifi cant decrease in vascular area fracti on was noted.
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FIGURE 3.3 Vessel length (A), number of microvessels per area (B), and vascular area fracti on (C) in control and 
nadroparin-treated animals for 9 days. Data represent mean ±SD.
Control (N = 20) Day 0 Day 3 Day 6 Day 9
L (cm/cm²) 61.8 ± 41 65.9 ± 21 65.2 ± 32 76.0 ± 74
N (n/cm²) 216.8 ± 80 280.8 ± 108* 270.3 ± 107* 340.2 ± 105°
VAF (%) 22.4 ± 6.3 20 ± 6.4* 19.7 ± 6.5* 25.6 ± 8.4°
Nadroparin (N = 21) Day 0 Day 3 Day 6 Day 9
L (cm/cm²) 65.4 ± 57 67.2 ± 23 61.8 ± 31 66.5 ± 54
N (n/cm²) 226.8 ± 80 222.2 ± 86a 179.4 ± 77*a 238.9 ± 87a
VAF (%) 23.8 ± 6.7 19.2 ± 7.4* 17.8 ± 5.0*a 15.6 ± 6.9°a
TABLE 3.1. Evoluti on of microvessel length, number, and area fracti on over ti me.
L, microvessel length; N, number of microvessels; VAF, vascular area fracti on; *P < 0.05 vs day 0; °P < 0.05 vs day 0, 3 and 6; aP < 0.05 vs 
untreated animals at corresponding ti me points. Data represent mean ± SD. 
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FIGURE 3.4 Microvessel diameter (A), red blood cell velocity (B), and volumetric blood fl ow (C) in control and nadroparin-
treated animals for 9 days. Data represent mean ± SD.
Control (N = 20) Day 0 Day 3 Day 6 Day 9
D (μm) 21.2 ± 16.1 23.1 ± 8.1 23.8 ± 9.3 26.5 ± 12.8*
V (mm/sec) 0.3 ± 0.1 0.4 ± 0.1* 0.4 ± 0.2* 0.3 ± 0.1#
VQ (pL/sec) 163.1 ± 159 135.8 ± 67* 151.6 ± 108* 171.5 ± 158*
Nadroparin (N = 21) Day 0 Day 3 Day 6 Day 9
D (μm) 21.6 ± 10.1 22.5 ± 7.9 24.2 ± 7.1* 24.4 ± 8.0*
V (mm/sec) 0.4 ± 0.1a 0.5 ± 0.2 0.4 ± 0.1 0.4 ± 0.1a
VQ (pL/sec) 130.4 ± 122a 161.7 ± 118 151.9 ± 102 156.8 ± 120*
TABLE 3.2. Evoluti on of microvessel diameter, red blood cell velocity, and volumetric blood fl ow over ti me.
D, microvessel diameter; V, red blood cell velocity; VQ, volumetric blood fl ow; *P < 0.05 vs day 0; #P < 0.05 vs day 3 and 6; aP < 0.05 vs 
untreated animals at corresponding ti me points. Data represent mean ± SD. 
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FIGURE 3.5 Microvessel density (FVIII staining) and fractal dimension in control and nadroparin-treated animals. (A, B) 
Examples of FVIII-stained microvessels of control and nadroparin-treated animals, respecti vely. Scale bar=25 μm. (C) 
Microvessel density. Columns= mean; Bars= s.d.; *P<0.001. (D) Microvessel fractal dimension. Columns=mean; Bars= 
s.d.; *P=0.029.
FIGURE 3.6 Microvessel maturity (pericyte coverage index) in control and nadroparin-treated animals. (A, B) Serial 
secti ons of FVIII- and αSMA-stained microvessels, respecti vely, in control hamsters. Weak αSMA staining is present 
around tumour microvessels, illustrati ng defi cient pericyte coverage. Scale bar=25 μm. (C) Area fracti on (percentage of 
stained pixels vs total number of pixels in binary images) of FVIII- and αSMA-stained cells. Columns=mean; Bars=s.d.; 
*P<0.001. (D) Microvessel pericyte coverage index. Columns=mean; Bars=s.d.; *P=0.012. 
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Eﬀ ects of nadroparin on the dynamic properti es of the tumour vascular bed
The results of microcirculatory calculati ons are summarised in Figure 3.4 and Table 3.2. 
In both groups, microvessel diameter increased signifi cantly over ti me, although in the 
nadroparin group the increase in diameter between days 6 and 9 was less pronounced. 
The evoluti on of microvessel RBC velocity is depicted in Figure 3.3B. In the control group, 
velocity increased progressively unti l day 6, followed by a signifi cant decline at day 9. In 
the experimental group, however, RBC velocity peaked earlier (day 3) and subsequently 
stabilised at a lower value. Volumetric blood fl ow increased signifi cantly over ti me in 
control animals, whereas nadroparin-treated animals show an early peak on day 3, 
followed by stable readings unti l the end of the experiment.
Immunohistochemical analysis
Histological examinati on of the dissected dorsal skinfolds on day 9 aft er tumour fragment 
implantati on showed macroscopically vital tumour ti ssue in all animals. Microvessel 
quanti tati ve and morphology data are illustrated in Figure 3.5. The microvessel density 
(FVIII staining) was 11.1% (6.2–18.1) in the control group and 4.5% (1.8–9.1) in the 
nadroparin-treated group (P<0.001, Mann–Whitney U-test). Fractal dimension was 
signifi cantly higher in control animals than in nadroparin-treated animals (1.5 (1.3–1.6) 
and 1.4 (1.3–1.5), respecti vely, P=0.029, Mann–Whitney U-test). 
Data concerning microvessel maturati on are depicted in Figure 3.6. The PCI was 73.6% 
(39.1–108.5) in untreated animals and 96.8% (74.3–126.1) in nadroparin-treated 
animals (P=0.012, Mann–Whitney U-test). The diﬀ erence in PCI between control and 
nadroparin-treated animals was more pronounced when the HaPT-1 cell line was used 
(Table 3.3). 
Amel 3 Control (N = 10) Nadroparin (N = 10)  P-value
FVIII 9.4 (5.2-15.1) 3.8 (1.4-6.6) < 0.001
SMA 5.1 (3.8-8.0) 1.7 (1.4-7.9) 0.020
PCI (%) 95.7 (54.5-117.9) 111.8 (63.3-134.3) NS
HaP-T1 Control (N = 10) Nadroparin (N = 11) P-value
FVIII 11.7 (6.9-19.9) 5.8 (2.4-10.7) < 0.001
SMA 10.9 (7.4-17.2) 5.8 (2.6-10.4) < 0.001
PCI (%) 76.5 (39.7-111.7) 108.3 (80.2-157.8) 0.003
TABLE 3.3. Immunohistochemistry results.
FVIII, factor VIII staining; SMA, smooth muscle anti gen staining; PCI, pericyte coverage index. Data represent median (interquarti le range).
3.1.5 Discussion 
The results from recent clinical studies in advanced cancer pati ents have led to increasing 
interest in the eﬀ ects of heparins on tumour growth. Klerk et al (2005) randomised 
advanced or metastati c cancer pati ents to either 6 weeks of nadroparin or placebo, and 
found a signifi cant overall survival benefi t in favour of nadroparin therapy (hazard rati o 
of mortality 0.75; 95% CI 0.59–0.96).
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The underlying mechanisms by which heparins inhibit tumour progression are 
incompletely understood, and may include inhibiti on of selecti n-mediated cellular 
adhesion, inhibiti on of tumour invasion, and inducti on of cancer cell apoptosis 
(Smorenburg and Noorden, 2001; Niers et al, 2007; Lee, 2007). 
One of the causal pathways under scruti ny is the inhibiti on of tumour-associated 
angiogenesis. Most in vivo angiogenesis assays, such as the mouse cremaster muscle 
or rat mesenteric window model, allow to observe the microcirculati on only once aft er 
therapy (Norrby, 2000; Wan et al, 2001). The dorsal skinfold chamber model allows 
noninvasive detailed and repeti ti ve analysis of tumour microvascular properti es (Torres 
et al, 1995). Our study is the fi rst to use repeti ti ve observati on in a dorsal skinfold window 
chamber model to assess the eﬀ ects of an LMWH on tumour-associated angiogenesis in 
an immunocompetent animal model.
Our results suggest that nadroparin exerts an anti angiogenic eﬀ ect in vivo, as evidenced 
by a signifi cantly lower vascular area fracti on and MVD when compared with control 
animals. Moreover, nadroparin-treated tumours showed signs of microvessel 
normalisati on, including a smaller increase in diameter, a higher PCI, and less vessel 
tortuosity (smaller fracti onal dimension). Vessel normalisati on is a well-characterised 
early phenotypic eﬀ ect of anti angiogenic therapy (Fukumura and Jain, 2008). The 
diﬀ erence in vessel diameter and tortuosity may explain the decrease in vascular area 
fracti on over ti me in nadroparin-treated animals despite the fact that both vessel length 
and vessel number did not change appreciably over ti me in this group.
Most of the published studies examining the anti angiogenic eﬀ ects of LMWHs have used 
physiological angiogenesis models such as the rat mesentery or matrigel plug assays. 
Mousa and Mohamed (2004) showed that the LMWH ti nzaparin inhibits angiogenesis in 
the chick chorioallantoic membrane model by upregulati on of the ti ssue factor pathway 
inhibitor. Tissue factor, which is the initi ator of the extrinsic coagulati on pathway, 
is expressed by many cancer types and was shown to promote tumour angiogenesis 
through protease-acti vated receptor 2 (PAR-2) signalling (Belti ng et al, 2004). Similarly, 
Marchetti   et al (2008) showed that the LMWHs, enoxaparin and dalteparin, but not 
unfracti onated heparin, signifi cantly inhibited capillary tube formati on in a Matrigel 
assay. Interesti ngly, the anti angiogenic potenti al of LMWHs seems to be depending on 
the size of the molecule and number of saccharide units. Khorana et al (2003) showed 
that molecules with a weight in the range of 3–6kDa or >8 saccharide units maximally 
inhibited angiogenesis in a Matrigel assay. Similar fi ndings were reported by Norrby 
(2000), who showed that 2.5–5kDa heparin fragments maximally suppressed VEGF-
induced angiogenesis in a rat mesenteric window assay. As the molecular weight of 
nadroparin is approximately 4.5kDa, our data confi rm the anti angiogenic potenti al of 
heparin fragments within the above-menti oned range.
The basic mechanisms underlying the anti -angiogenic eﬀ ect of the LMWHs remain to be 
elucidated. Several potenti al pathways have been proposed. First, LMWHs suppress TF 
gene expression and enhance the release of TF pathway inhibitor (Mousa and Mohamed, 
2000; Schultz et al, 2001). Second, heparin fragments smaller than 18 saccharide units 
were shown to interfere with the binding of VEGF to its cellular receptor (Soker et al, 
1994). In additi on, heparins inhibit the release of heparanase by malignant ti ssue (Parish 
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et al, 1999, 2001). Heparanase not only creates a pro-angiogenic environment through 
the release of heparin-bound growth factors (VEGF, bFGF) from the intersti ti al matrix 
and upregulati on of TF and VEGF expression, but is also a key enzyme in the degradati on 
of this matrix, which renders it ‘permissive’ for neovascular outgrowth (El-Assal et al, 
2001; Wood et al, 2005). Indeed, Collen et al (2000) found that structural alterati ons 
of the fi brin matrix induced by LMWH reduced the invasion of capillary-forming ECs. 
Nadroparin may exert a similar eﬀ ect on ECM properti es, as Barner et al (1987) found 
that in vitro, LMWH with a mean weight of 4.5kDa inhibited 99% of heparanase acti vity. 
In additi on to a decrease in the number of microvessels, several other structural eﬀ ects 
were found to result from nadroparin administrati on in this study. It is noteworthy 
that microvascular diameter at day 9 was signifi cantly smaller compared with control 
animals. Theoreti cally, this may be explained by the inhibiti on bFGF and PDFG acti vity, 
which both exert a vasodilatory acti vity (Pukac et al, 1997; Takase et al, 1999; Millett e 
et al, 2005). 
The higher PCI and more eﬃ  cient perfusion that we found in nadroparin-treated 
animals suggest a normalising eﬀ ect of this LMWH on the tumour’s vascular bed. As a 
consequence, there may be a role for LMWH to enhance drug delivery of concurrently 
administered cytotoxic therapy. In pati ents with pancreati c cancer and small cell lung 
cancer, administrati on of LMWH enhanced the eﬃ  cacy of combined chemotherapy (Icli 
et al, 2002; Alti nbas et al, 2004).
Several limitati ons apply to the interpretati on of the current results. First, although it 
may be assumed that inhibiti on of tumour angiogenesis in this model translates into 
inhibiti on of tumour growth, this could not be assessed because of the short ti me 
frame used (9 days). Second, implantati on of window chambers invariably induces a 
certain degree of infl ammati on that might confound the fi ndings related to tumour 
angiogenesis. Finally, it is unclear to what extent fi ndings in a heterotopic animal tumour 
model will translate into relevant clinical eﬀ ects in pati ents.
In additi on to the uncertain basic mechanisms by which heparins interfere with 
tumour angiogenesis, several other questi ons remain open. It is unclear whether the 
anti angiogenic eﬀ ects of LMWHs depend only on their molecular weight and number 
of saccharide units, or also on other physicochemical properti es such as manufacturing 
process and degree of sulphati on. In additi on, although most of the mechanisms shown 
thus far suggest a rather generic mode of acti on, preclinical studies suggest that the 
anti tumour eﬀ ects of heparins depend on the cancer cell type (Niers et al, 2009). Finally, 
the LMWH dose and durati on in the clinical setti  ng remain to be determined.
In conclusion, nadroparin inhibits tumour-associated angiogenesis and normalises 
microvessel structure in this immunocompetent tumour model using the dorsal 
skinfold chamber. Further study is required to determine whether direct eﬀ ects on EC 
proliferati on and modelling, changes in the structure of the extracellular matrix, or both 
explain our observati ons.
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Chapter 3.2: Intravital microscopy to study the microvascular
eﬀ ects of nadroparin versus enoxaparin in colorectal tumour
angiogenesis
I Debergh,1 N Rosseel,1 P Patt yn,1 and WP Ceelen1
1Department of Surgical Oncology, University Hospital, B-9000 Ghent, Belgium
Submitt ed
3.2.1 Abstract
Background: Heparin or LMWH might improve survival in subgroups of cancer pati ents 
with bett er prognosis, independent of their anti coagulant eﬀ ect. The specifi c anti cancer 
mechanism of LMWH is not completely understood. Diﬀ erent pathways are infl uenced, 
e.g. infl uencing tumour cell proliferati on, invasion, angiogenesis and metastasis. In our 
study, we try to elucidate the microcirculatory anti angiogenic eﬀ ect of nadroparin and 
enoxaparin on colorectal angiogenesis in a mouse xenograft  dorsal window chamber 
model using IVM studies and immunohistochemistry.
Methods: HT29 human colorectal cancers were implanted in a dorsal skinfold window 
chamber in athymic mice. Animals (N=8 per group) were treated with 200 IU of 
nadroparin, enoxaparin or saline for 8 days. Repeated intravital fl uorescence microscopy 
was performed to calculate functi onal microcirculatory parameters: number (N) and 
length (L) of microvessels, vascular area fracti on (AF), and red blood cell velocity (V). 
Microvessel density (MVD), fractal dimension, and pericyte coverage were assessed 
histologically.
Results: Acti ve angiogenesis was observed in control animals, resulti ng in a signifi cant 
increase in N, L, and AF. In nadroparin- and enoxaparin-treated animals, however, AF 
did not change signifi cantly over ti me and N and L remained signifi cantly lower than 
untreated animals on day 7. Compared with control animals, nadroparin- and enoxaparin-
treated animals showed a signifi cantly lower MVD, but a higher PCI depicti ng a more 
mature microvessel network.
3.2.2 Introducti on
Cancer pati ents are at risk of venous thromboembolic events (VTE) induced by the 
hypercoagulable state associated with malignancy (Mousa S., 2004). There is therefore 
a clear rati onale for prophylacti c administrati on of unfracti onated heparin (UFH) or 
low molecular weight heparin (LMWH) in these pati ents (Carrier & Agnes, 2009). Both 
UFH and LMWH exert their anti coagulant eﬀ ect by acti vati ng anti thrombin (AT), which 
neutralizes a number of serine proteases in the clotti  ng cascade, notably thrombin 
and factor X. Current internati onal guidelines recommend LMWH as gold standard 
anti coagulant prophylaxis (Lyman, et al., 2013).
Recent clinical studies have suggested that, independent from its eﬀ ects on the 
incidence of VTE, heparin therapy might alter survival in cancer pati ents (Kakkar, et al., 
2004; Klerk, et al., 2005). In the FAMOUS trial, 385 pati ents with advanced malignancy 
where randomized to receive either dalteparin (Fragmin, mean mol weight 5 kDa) 5000 
IU once daily or placebo. Overall survival aft er 1, 2 or 3 years did not diﬀ er between two 
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groups. In a post hoc subgroup analysis of pati ents with a bett er prognosis, however, 
survival was signifi cantly improved in dalteparin treated pati ents (55% versus 36% aft er 
3 years, p=0.03). Another recent trial randomized advanced cancer pati ents to either 
nadroparin (Fraxiparine, 5.5 kDa) 0.4-0.8 ml or placebo during 6 weeks. In a predefi ned 
subgroup of pati ents with bett er prognosis, the hazard rati o was 0.64 (95%CI: 0.45-0.9) 
in favour of the nadroparin group while the incidence of major bleeding did not diﬀ er 
signifi cantly. Enoxaparin (Clexane, 4.5 kDa), the worldwide most used LMWH, may also 
have a positi ve eﬀ ect on survival, for instant by prolonging the ti me to progression in 
pati ents with metastati c non-small cell lung cancer (Robert, Busby, Marques, Reynolds, 
& Carey, 2003).
The mechanisms through which LMWHs exert anti cancer eﬀ ects remain incompletely 
understood. Several aspects of cancer growth including tumor cell proliferati on, 
invasion, angiogenesis and metastasis have been examined in relati on to the eﬀ ects of 
heparin (Niers, et al., 2007; Mousa & Petersen, 2009).
Most experimental data thus far were generated from cell culture experiments. In vivo 
microscopy (IVM) allows to repeatedly and noninvasively examine tumour associated 
angiogenesis through an implanted glass covered observati on window. A recent study 
shows favorable anti angiogenic results in melanoma and pancreati c carcinoma of 
nadroparin in a hamster model (Debergh, Van Damme, Patt yn, Peeters, & Ceelen, 2010). 
The aim of the present experiment is to study the eﬀ ects of nadroparin and enoxaparin 
on colorectal angiogenesis in a mouse xenograft  dorsal window chamber model using 
IVM studies and immunohistochemistry. The use of IVM in this setti  ng represents a good 
approach to study the interacti ons of LMWHs with tumor microcirculatory events.
3.2.3 Methods
ANIMAL AND TUMOR MODEL
Athymic mice (athymic nu/nu, Harlan, The Netherlands) weighing 25-30g were housed 
separately in plasti c cages with free access to tap water and standard pellet food.
HT29 human colon cancer cell lines were cultured in McCoy’s 5A (Gibco life technologies, 
Invitrogen) and 1 million cells suspended in 0.05 mL of PBS (phosphate-buﬀ ered saline, 
Gibco life technologies, Invitrogen) were injected in the dorsal window chamber (on day 
1 aft er implantati on) as xenograft s.
DORSAL SKINFOLD CHAMBERS IMPLANTATION
Mice were anaestheti sed using isofl urane inhalati on (1.5-2%) and placed on a heati ng 
pad. A ti tanium frame is surgically fi xed onto a dorsal skinfold of the animal. On one 
side of the skinfold, a circular area of dermis and subcuti s is surgically removed (10 
mm diameter) and covered by a circular cover glass. Animals were housed separately 
and were allowed to recover for 24h from surgery and anaesthesia before tumour 
suspension was injected. Window chambers were inspected daily for the presence of 
air bubbles, infl ammati on, infecti on, or vascular thrombosis.
DRUG THERAPY
Animals (N = 8 per group) were treated with daily intraperitoneal injecti ons of either 
0.05 mL of saline, 200 IU aXa of nadroparin dissolved in 0.1 mL of saline, or 200 IU aXa 
of enoxaparin dissolved in 0.1 mL of saline. Injecti ons started the day before tumour 
implantati on.
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IN VIVO MICROSCOPY (IVM)
In vivo fl uorescence microscopy was performed on days 1 (day of tumour injecti on), 3, 
5, and 7. Unconscious animals (isofl urane inhalati on) received an i.v. bolus of 0.03 mL of 
fl uorescein isothiocyanate (FITC)-labelled dextran (20 mg/mL) (MW 150 000 Da; Sigma-
Aldrich NV, Bornem, Belgium) and were placed on the stage of a modifi ed Olympus 
BX51W1 microscope (Olympus NV, Aartselaar, Belgium). Fluorescence microscopy was 
performed using a HBO 50W mercury lamp (Osram, Zaventem, Belgium) and a FITC fi lter 
set (excitati on fi lter 460-490 nm) for detecti ng epifl uorescent intravascular plasma. Stati c 
and dynamic images of the microcirculati on were obtained in 4 diﬀ erent regions in each 
chamber. Digital images were captured real ti me on the hard disc of a computer using 
a high sensiti vity digital camera (model C8484-05, Hamamatsu Photonics, Hamamatsu, 
Japan). Quanti tati ve microcirculatory analysis was performed using the Capimage 
soft ware (H Zeintl Engineering, Heidelberg, Germany). The following parameters were 
calculated: microvessel length per area (L; cm/cm²), number of microvessels per high-
power fi eld (N; n/HPF x20), vascular area fracti on (AF; %), and microvessel diameter (D; 
μm). In additi on, centerline red blood cell velocity (V; mm/s) was measured by analyzing 
10 microvessels per region of interest, randomly chosen among those that crossed a 
verti cal line drawn over the centre of the computer screen, as described by Laschke et 
al. (2005). Volumetric blood fl ow (VQ; pL/s) was calculated from V and D as VQ = π x 
(D/2)² x V/K, in which K (= 1.3) represents the Baker-Wayland factor (Baker & Wayland, 
1974), and considers the parabolic velocity profi le of blood in microvessels.
On day 8 aft er skinfold chamber implantati on, animals were killed and the ti ssue inside 
the observati on window was excised for histology. Tissue fragments were fi xed in 10% 
formalin, embedded in paraﬃ  n, and 4 μm thick secti ons were cut and mounted for 
immunohistochemistry.
IMMUNOHISTOCHEMISTRY
Factor VIII (von Willebrand factor, FVIII) immunostaining was used to visualize tumour 
microvessels and calculate microvessel density (MVD), whereas α-smooth muscle acti n 
(αSMA) was used to identi fy pericytes and calculate the pericyte coverage index (PCI) as a 
measure of microvessel maturati on. Serial ti ssue secti ons were deparaﬃ  nised in xylene, 
hydrated by serial immersion in ethanol, and subsequently incubated in Proteinase K 
(Dako, Heverlee, Belgium) for anti gen retrieval. Endogenous peroxidase acti vity was 
blocked with 3% H2O2 in methanol. Slides were washed in Tris-buﬀ ered saline (TBS) –
Tween and treated with UltraSens Block RTU (ImmunoLogic, Duiven, The Netherlands) to 
inhibit nonspecifi c anti body binding. Secti ons were incubated with mouse monoclonal 
anti bodies against FVIII (Dako) or αSMA (Abcam, Cambridge, UK) at room temperature 
for 1h, rised with TBS-Tween, and incubated with secondary anti bodies (UltraSens 
Bioti nylated Goat Anti -polyvalent RTU; ImmunoLogic) for 10 min each. Visualisati on of 
the immunoprecipitate was performed by adding 3,3’-diaminobenzidine (Biogenex, San 
Ramon, CA, USA) and counterstaining with haematoxylin. Positi ve and negati ve controls 
were processed simultaneously.
Serial FVIII and αSMA- stained secti ons of dorsal skinfold ti ssue were enti rely scanned 
for tumour regions (magnifi cati on x20) and digiti zed. Microvessel density was calculated 
by digital image analysis using the NIH ImageJ soft ware (version 1.47, available from 
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htt p://rsbweb.nih.gov/ij). Using the threshold colour plugin, FVIII and αSM-positi ve 
cells were isolated from background staining and the resulti ng images converted to 
binary. Microvessel density was calculated using the rati o of black pixels over the total 
number of pixels in the binary image, whereas the PCI was calculated as the rati o of 
αSMA-positi ve pixels vs FVIII-positi ve pixels. The fractal dimension of the microvessel 
bed was calculated using the ImageJ FracLac plugin. The fractal dimension is a rati onal 
number between 1 and 2 (the dimensions of a line and plane, respecti vely), and has 
been shown to correlate with the degree of branching, tortuosity, and irregularity of the 
tumour-associated microvessel network (Dey, 2005).
STATISTICAL ANALYSIS
Data are expressed as median (interquarti le range). As the distributi on of all the variables 
may not be Gaussian, diﬀ erences were analysed using Mann–Whitney rank-sum test 
or diﬀ erences between more than two groups were analysed by ANOVA. Results were 
considered stati sti cally signifi cant when the probability of a type I error was ≤ 5%. 
Stati sti cal analysis was performed with SigmaPlot 11.0 (Systat Soft ware, Richmond, CA, 
USA).
3.2.4 Results
All animals (n = 24) developed tumour-induced angiogenesis, microscopically visible in 
the observati on window (Figure 3.7). Three animals were excluded on day 1 for further 
analysis because of insuﬃ  cient opti cal quality of the window chamber. In all other 
animals (N=21), the skinfold chamber provided excellent image quality and resoluti on 
over the durati on of the experiment (7 days).
Eﬀ ects of nadroparin and enoxaparin on tumour-induced angiogenesis
The microvascular parameters derived from in vivo microscopic observati ons are 
summarised in Figure 3.8A-C and Table 3.4A. In control animals (N=7), the number 
and the length of microvessels and the vascular area fracti on increased signifi cantly. 
In nadroparin- and enoxaparin-treated animals (N=7 each), however, vascular area 
fracti on did not change signifi cantly over ti me. A signifi cant increase in the number and 
the length of microvessels was also noted in the LMWH-treated groups, but the result 
at day 7 remained signifi cantly lower than untreated animals.
Eﬀ ects of nadroparin and enoxaparin on the dynamic properti es of the tumour vascular 
bed
The results of microcirculatory calculati ons are summarised in Figure 3.8D-F and Table 
3.4B. In treated groups, microvessel diameter did not change signifi cantly over the 
course of 7 days of tumour evoluti on, compared to untreated animals. In the nadroparin 
group, a further signifi cant decrease of diameter was observed on day 7 when compared 
to diameters of the enoxaparin-treated group.
In the control group, velocity and volumetric blood fl ow increased progressively unti l 
day 5, followed by a decline at day 7. In the enoxaparin-treated group, RBC velocity has 
the same tendency, whereas volumetric blood fl ow peaked earlier.
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FIGURE 3.7 Representati ve tumour growth and angiogenesis observed for 7 days in a control animal (A-D), a nadroparin- 
(E-H) and an enoxaparin-treated animal (I-L). IVM evaluati on was done on day 1 (A,E,I), day 3 (B,F,J), day 5 (C,G,K), and 
day 7 (D,H,L). Scale bar = 200μm.
In nadroparin-treated animals dynamic properti es of red blood cell are completely 
diﬀ erent. A signifi cant higher RBC velocity and volumetric blood fl ow compared to 
enoxaparin treated animals was measured at day 1, with a stati sti cally signifi cant drop in 
velocity and fl ow at day 3 compared to both other groups. At day 5 and 7 no diﬀ erences 
in velocity or volumetric blood fl ow between the groups are observed.
Immunohistochemical analysis
Histological examinati on of the dissected dorsal skinfolds on day 8 aft er tumour fragment 
implantati on showed macroscopically vital tumour ti ssue in all animals. Microvessel 
quanti tati ve and morphology data are illustrated in Figure 3.9A-D. The microvessel 
density (FVIII staining) was 7.6% (4.4-10.8) in the control group, 5.5% (3.5-7.4) in the 
nadroparin-treated group, and 3.9% (2.1-8.1) in the enoxaparin-treated group (P < 0.05, 
ANOVA on ranks) (Table 2).
Data concerning microvessel maturati on are depicted in Figure 3.9E. The PCI was 77.9% 
(50.0-118.1) in untreated animals, 112.2% (60.2-179.0) in nadroparin-treated animals 
and 106.5% (43.6-216.2) in enoxaparin-treated animals (P = 0.005 and P = 0.034, 
respecti vely; Mann–Whitney U-test) (Table 3.5).
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FIGURE 3.8 Vessel length (A), number of microvessels per area (B), vascular area fracti on (C), microvessel diameter (D), 
red blood cell velocity (E), and volumetric blood fl ow (F) in control, nadroparin- and enoxaparin-treated animals for 7 
days.
*P<0.05 vs day 1; **P<0.05 vs day 1 and 3; ***P<0.05 vs day 1, 3 and 5; °P<0.05 vs day 3; °°P<0.05 vs day 3 and 5; aP<0.05 vs untreated 
animals; bP<0.05 vs treatment with enoxaparin.
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A Day 1 Day 3 Day 5 Day 7
Control (n = 7)
L (cm cm-²) 127,9 (110,7-148,8) 155,5 (121,1-174,6) 223,5 (186,4-262,5)** 262,8 (233,5-310,1)**
N (n cm-²) 70,7 (61,8-85,2) 99,2 (74,8-120,3) 168,3 (124,7-220,1)** 243,5 (203,6-293,8)***
VAF (%) 40,6 (29,2-48,5) 49,7 (41,0-54,6)* 50,9 (40,1-56,1)* 49,2 (44,9-56,7)*
Fractal Dimension 1,67 (1,63-1,72) 1,69 (1,65-1,76) 1,70 (1,66-1,74) 1,69 (1,66-1,74)
Nadroparin (n = 7)
L (cm cm-²) 133,9 (118,1-150,5) 132,4 (110,9-151,5)a 164,4 (144,6-183,5)a** 173,7 (145,7-203,6) a**
N (n cm-²) 79,7 (63,1-90,2) 81,2 (66,2-99,2)a 96,8 (79,4-114,1)a** 101,7 (80,0-134,0)a**
VAF (%) 40,3 (34,0-48,5) 42,4 (32,6-48,9) 43,5 (36,8-50,1) 39,7 (32,5-45,2)a
Fractal Dimension 1,69 (1,64-1,73) 1,70 (1,64-1,75) 1,68 (1,64-1,73) 1,72 (1,67-1,76)
Enoxaparin (n = 7)
L (cm cm-²) 125,8 (106,2-144,8) 139,0 (116,3-165,4) 173,5 (142,9-186,7)a** 147,7 (123,7-169,8)a*
N (n cm-²) 69,5 (54,6-81,9) 83,1 (69,5-98,0)* 116,6 (86,2-136,5)a** 101,0 (73,5-125,3)a*
VAF (%) 38,1 (34,5-47,9) 44,9 (35,4-50,7) 43,3 (35,2-50,2)a 43,8 (31,6-51,0)a
Fractal Dimension 1,68 (1,62-1,74) 1,70 (1,66-1,74) 1,70 (1,65-1,75) 1,71 (1,65-1,75)
B Day 1 Day 3 Day 5 Day 7
Control (n = 7)
D (μm) 15,0 (13,5-24,1) 21,3 (15,0-30,1)* 20,5 (14,9-27,7)* 21,3 (15,0-28,4)*
V (μm / s) 170,2 (67,4-354,0) 246,1 (163,5-410,8)* 247,0 (131,2-505,4)* 180,7 (85,6-365,1)°°
VQ (pL / s) 29,6 (10,7-70,1) 74,0 (34,2-163,5)* 69,6 (27,8-165,1)* 50,7 (19,2-141,1)***
Nadroparin (n = 7)
D (μm) 16,7 (13,5-21,3) 15,0 (13,5-21,1) a 15,0 (13,5-20,5) a 14,9 (13,5-20,2)ab
V (μm / s) 206,5 (132,0-321,6)b 184,7 (96,1-313,5)ab 257,4 (126,2-370,9)° 212,6 (96,2-384,5)
VQ (pL / s) 35,9 (16,9-77,8)ab 26,9 (14,1-61,0)ab 37,1 (19,7-65,1)°a 34,7 (13,9-67,2)a
Enoxaparin (n = 7)
D (μm) 16,8 (13,5-22,5) 16,8 (13,8-22,5)a 15,0 (13,5-21,3)a 16,8 (13,8-24,2)a
V (μm / s) 144,0 (85,3-293,3) 209,1 (132,6-424,8)* 222,4 (126,0-415,9)* 193,3 (122,5-373,3)*
VQ (pL / s) 26,5 (11,6-65,6) 45,1 (20,8-97,3)*a 37,5 (15,6-84,4)*a 35,0 (14,3-89,2)*a
TABLE 3.4 (A) Evoluti on of microvessel length, number, and area fracti on over ti me. (B) Evoluti on of microvessel diameter, 
red blood cell velocity, and volumetric blood fl ow over ti me.
Abbreviati ons: L = microvessel length; N = number of microvessels; VAF = vascular area fracti on. D = microvessel diameter; V = red blood 
cell velocity; VQ = volumetric blood fl ow.
*P<0,05 vs day 1; **P<0,05 vs day 1 and 3; ***P<0,05 vs day 1, 3 and 5; °P<0,05 vs day 3; °°P<0,05 vs day 3 and 5; aP<0,05 vs untreated 
animals and bP<0.05 vs enoxaparin-treated animals at corresponding ti me points. Data represent median (interquarti le range).
TABLE 3.5 Immunohistochemistry results
Abbreviati ons: FVIII = factor VIII staining; αSMA = α-smooth muscle acti n staining; PCI = pericyte coverage index. Data represent median 
(interquarti le range). aP<0,05 vs untreated animals and bP<0.05 vs enoxaparin-treated animals.
 Control (n = 7) Nadroparin (n = 7) Enoxaparin (n = 7)
FVIII (%) 7,6 (4,4-10,8) 5,5 (3,5-7,4)a 3,9 (2,1-8,1)a
αSMA (%) 5,2 (3,8-6,9) 5,6 (3,4-7,7)b 4,0 (2,8-6,0)
PCI (%) 77,9 (50,0-118,1) 112,2 (60,2-179,0)a 106,5 (43,6-216,2)a
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FIGURE 3.9 Examples of FVIII-stained microvessels of control (A), enoxaparin- (B) and nadroparin-treated (C) animals. 
Scale bar = 100μm.
Microvessel density (FVIII-staining) (D) in the three experimental groups. Box plot shows median values and interquarti le 
ranges, with dots expressing 5th-95th percenti les.
Microvessel maturity (pericyte coverage index) (E) in the three experimental groups. Columns = median; Bars = 
interquarti le range. aP<0.05 vs untreated animals.
3.2.5 Discussion
Anti cancer properti es of heparins and LMWHs are the topic of intensive experimental 
research for several decades. Important variati on in study design, animal models, 
and tumour type makes interpretati on and comparison diﬃ  cult. Variati ons include 
the type of heparin or LMWH used, heparin dose and durati on of treatment, interval 
between heparin administrati on and cancer cell inoculati on and route of administrati on 
(subcutaneous (s.c.), intraperitoneal (i.p.) or intravenous (i.v.)).
The eﬀ ect on primary tumour growth was investi gated in s.c. tumour models, where 
only high doses of heparins (i.p. or s.c.) demonstrated signifi cant anti tumour acti vity 
(Back & Steger, 1976; Niers, et al., 2007). In several studies, heparin administrati on into 
the peritoneal cavity reduced the peritoneal tumour deposits. These fi ndings suggest 
that high heparin concentrati ons around the tumour cells could excert a local eﬀ ect. 
Other studies reveal that (even lower doses of) heparin and LMWH induce a signifi cant 
reducti on in the number of metastases. Also, not only heparins but modifi ed heparins 
with limited or no anti coagulant acti vity were used, and showed to have tumour 
growth reducing or anti -metastati c properti es, which proves that the eﬀ ect is not only 
dependent on the inhibiti on of coagulati on (Niers, et al., 2007).
The topic of our study is the eﬀ ect of LMWH on tumour-associated angiogenesis
alone, which has a pivotal role in successful growth of tumour and spreaded metastases. 
Our results suggest that both nadroparin and enoxaparin exert an anti angiogenic eﬀ ect 
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in a human colorectal tumour mouse model, as evidenced by a signifi cantly lower 
vascular area fracti on, microvessel density, length and number of microvessels when 
compared with control animals (Figure 3.8A-C and 3.9D). Indeed, Marchetti   et al. 
(2008) demostrated that the LMWHs, enoxaparin and dalteparin, signifi cantly inhibited 
capillary tube formati on in a Matrigel assay. A former study, with a dorsal chamber 
skinfold model in hamsters, inoculated with pancreati c carcinoma or melanoma, and 
treated with 200 IU s.c. nadroparin only proved to provoke lower vascular area fracti on 
and MVD than control animals, but had no eﬀ ect on length and number of microvessels 
(Debergh, Van Damme, Patt yn, Peeters, & Ceelen, 2010). The current anti angiogenic 
eﬀ ect on L and N, can possibly be explained by the relati vely higher dosages of LMWHs 
in mice (200 IU) and not by diﬀ erent route of administrati on (i.p. vs s.c.).
Angiogenesis is a criti cal process in malignant growth regulated by a number of heparin 
binding angiogenic growth factors such as vascular endothelial growth factor (VEGF) 
and basic fi broblast growth factor (bFGF). These angiogenic growth factors bind to 
heparane sulphate proteoglycans (HSPGs) present on both the endothelial cells (ECs) 
and the extracellular matrix (ECM). Soluble heparins have been shown to compete 
with growth factors for ECM binding sites, and therapeuti c dosages of UFH cause 
an increase in plasma levels of certain growth factors (Colin, et al., 1999; Folkman, 
Weisz, Joullie, Li, & Ewing, 1989). In contrast to UFH, LMWH has been shown to inhibit 
binding of angiogenic growth factors to their endothelial receptors, an eﬀ ect that is 
depending on the number of sulphated polysaccharide glycosaminoglycan chains in the 
heterogenous mixture of LMWH (Norrby, 1993). In a Matrigel assay, endothelial cell 
proliferati on and tube formati on was inhibited maximally by LMWH with a chain length 
of >8 polysaccharides and a molecular weight of 6 kDa while no inhibiti on was observed 
with UFH, tetrasaccharide, pentasaccharide, or octasaccharide (Khorana, Sahni, Altland, 
& Francis, 2003). Also in vitro, heparin fragments of less than 18 saccharides reduce 
the acti vity of VEGF (Soker, Goldstaub, Svahn, Vlodavsky, Levi, & Neufeld, 1994) and 
fragments of less than 10 saccharide residues inhibit the acti vity of bFGF (Lepri, et al., 
1994). In vivo, the same eﬀ ect of small heparin fracti ons on bFGF acti vity has been 
described (Jayson & Gallagher, 1997; Norrby & Ostergaard, 1996). Similar fi ndings were 
reported by Norrby (2000), who showed that 2.5–5kDa heparin fragments maximally 
suppressed VEGF-induced angiogenesis in a rat mesenteric window assay.
So, the anti angiogenic potenti al of LMWHs seems to be depending on the molecular 
weight and number of saccharide units. In our experiment, we compared the in vivo 
eﬀ ect of commercially available nadroparin (4.3 kDa) and enoxaparin (4.5 kDa) on 
tumour angiogenensis with similar molecular weights. Small diﬀ erences in results can 
be explained by diﬀ erent polysaccharide mixtures, e.g. enoxaparin is composed of 70-
80% characterizable 2 to 12 saccharides (< 3600 Da). The 20-30% remaining mixture is 
incompletely known and contains 13 to 32 saccharides (> 3600 Da). As these LMWHs 
are polysaccharide mixtures, both bFGF and VEGF can be targeted in the anti angiogenic 
process, which is a plausible explanati on of the positi ve short term results on tumour-
associated angiogenesis. It is known that in pati ents receiving bevacizumab, a monoclonal 
anti -VEGF anti body, therapy resistance or disease progression can be expected due 
to the upregulati on of placental growth factor (PlGF), platelet-derived growth factor 
(PDGF) and bFGF (Saif, 2013).
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Another criti cal event in the process of cancer invasion, metastasis or tumoural 
angiogenesis is the degradati on of various components of the ECM, including collagen, 
laminin, fi bronecti n and HSPGs. This can be obtained by heparanase, secreted by cancer 
cells. Heparanase expression is rare in normal ti ssue, but is evident in many human 
tumours where it signifi cantly increases both the angiogenic and metastati c potenti al 
of cancer cells (Vlodavsky, Korner, Ishai-Michaeli, Bashkin, Bar-Shavit, & Fuks, 1990). 
In vitro, LMWH with a mean weight of 4.5kDa inhibited 99% of heparanase acti vity
(Bar-Ner, et al., 1987). Thus, nadroparin- and enoxaparin-induced blocking of heparanase 
could possibly make the ECM less permissive for tumoural neovasculature. Indeed, 
structural alterati ons of the fi brin matrix induced by LMWH reduced the invasion of 
capillary-forming endothelial cells (Collen, et al., 2000).
Our study also describes a stati sti cally signifi cant increase in PCI, thus a bett er maturati on 
of microvessels compared to tumoural vessels due to treatment with enoxaparin and 
nadroparin (fi gure 5). An angiogenic signal (f.i. VEGF or bFGF) coming from tumour 
cells, will detach pericytes from the vessel wall and make endothelial cells loosen 
their juncti ons; as a consequence this pathological vessel dilates. VEGF increases the 
permeability of the endothelial cell layer, causing plasma proteins to extravasate and to 
increase the intersti ti al pressure (Carmeliet & Jain, 2011). Currently, vessel normalizati on 
appeared to be able to open new therapeuti c opportuniti es to slow down tumour 
invasiveness and disseminati on, and increase tumour responses to chemotherapeuti cs 
and radiotherapy than anti -angiogenic therapy alone (Jain, 2002). Besides the increased 
PCI (Figure 3.9E), we also observed a normalized diameter aft er 7 days of treatment 
with nadroparin and enoxoparin in tumoural microvessels (Figure 3.8D). Unfortunately, 
our current study did not measure microvessel permeability nor its normalizati on aft er 
treatment, which however, can be easily done in the IVM model. Furthermore, this 
model has some limitati ons as measuring plasma and intersti ti al oncoti c pressure, or 
hypoxia in the tumor is not technically feasible.
Tumoural microvessel hemodynamic properti es change also during treatment with 
LMWHs. Red blood cell velocity tend to increase signifi cantly from day 3-5 aft er tumour 
implantati on, to sati sfy the high demands of early tumour formati on (Lin, et al., 2010). 
On day 7, a signifi cant decrease in velocity is observed (Figure 3.8E), probably due to 
increased intersti ti al pressure in the leaking vascular bed. Hence, volumetric blood 
fl ow follows the same patt ern. Enoxaparin-treated tumoural microvessels, have also 
a signifi cant increase of blood fl ow between 3-5 days, but tend to decrease on day 7 
(Figure 3.8F). As microvessel diameter is normalized in these animals, volumetric blood 
fl ow is signifi cantly lower on day 5 and 7 compared to control animals and tends to 
normalize again. Nadroparin treatment reveals other hemodynamic properti es with a 
high red blood cell velocity on day 1 and a signifi cant lower velocity on day 3 compared 
to both other groups. From day 5 on, red blood cell velocity follows more or less the 
patt ern of both other groups. Whether a nadroparin-infl icted eﬀ ect on the intersti ti al 
pressure during day 1 and 3 is the cause of this aberrant velocity patt ern, and concomitant 
volumetric blood fl ow patt ern, must be elaborated in future studies. At day 5 and 7, 
volumetric blood fl ow in nadroparin treated groups has a tendency to normalize, with 
signifi cant lower values than control animals at corresponding ti me points.
Several limitati ons can be found in our study. Besides exploring the eﬀ ect of LMWHs 
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on microvessel normalizati on more thoroughly, we must examine dose-response eﬀ ect 
of LMWHs and durati on of treatment not only in animal models, but also in the clinical 
setti  ng. For future experiments, it would be useful to quanti fy vascular normalizati on 
properti es of LMWH in a similar in vivo tumour model, with additi onal measurements 
of permeability of the microvasculature, ti ssue oxygen pressure and intersti ti al fl uid 
pressure.
Encouraging however, is that the anti tumour eﬀ ects of heparins with vascular 
normalizati on, which are depending on the cancer cell type, could be validated in a 
hamster model with melanoma and pancreati c carcinoma, and now in a mouse xenograft  
model with human colorectal cancer.
In conclusion, nadroparin and enoxaparin inhibit tumour-associated angiogenesis 
and normalizes microvessel structure in this mouse xenograft  model using the dorsal 
skinfold chamber. Further study is required to determine whether direct eﬀ ects on EC 
proliferati on and modelling, changes in the structure of the extracellular matrix, or both 
explain our observati ons.
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4.1.1 Abstract
Cancer is rapidly becoming the worldwide leading cause of premature death. 
Iconographic techniques have traditi onally provided informati on on tumor anatomy. 
The recent introducti on of functi onal and molecular imaging techniques allows probing 
tumor physiology and biology in additi on to mere anatomical descripti on. In additi on 
to the research implicati ons, these novel imaging techniques oﬀ er early response 
assessment and target visualizati on which, in the era of personalized medicine, may 
oﬀ er signifi cant advances in cancer therapy. Here, we provide an overview of the most 
important developments in cancer imaging, with a focus on the clinical applicati ons.
4.1.2 Introducti on
Cancer is a leading cause of death worldwide, accounti ng for well over 7 million deaths 
in 2008 [1]. Since most solid cancers are not readily amenable for palpati on and 
inspecti on, accurate imaging has traditi onally been one of the cornerstones of cancer 
therapy. Indeed, imaging allows for correct anatomical delineati on and staging of the 
malignant process, which have a direct impact on the therapeuti c strategy as well as 
the pati ent’s prognosis. Unti l the beginning of the 21st century, medical iconography 
was primarily focused on anatomical imaging, with computed tomography (CT) and 
magneti c resonance imaging (MRI) being the most important imaging technologies. 
These structural imaging modaliti es can oﬀ er images with exquisite spati al resoluti on 
within seconds or minutes, but they share the limitati on of not being able to detect 
lesions unti l the structural changes in the ti ssue (e.g. tumor growth) are large enough to 
be detected by these imaging technologies [2].
Recent advances in molecular and functi onal imaging have had a signifi cant impact 
on modern oncology practi ce. First, nuclear techniques such as positron emission 
tomography (PET) and single-photon emission CT (SPECT) oﬀ er the potenti al of detecti ng 
cellular or molecular changes which precede structural abnormaliti es. Obviously, these 
techniques, when combined with novel molecular tracers, also hold considerable 
promise in early drug development. Secondly, functi onal and molecular imaging allow 
for rapid assessment of therapy response, which allows disease biology to gauged well 
before any change in tumor dimension occurs as measured by the traditi onal RECIST 
criteria [3]. The use of imaging as a biomarker of response allows tailoring the therapeuti c 
strategy and limiti ng the cost and side eﬀ ects of ineﬀ ecti ve regimens. Here, we review 
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the currently available functi onal and molecular imaging modaliti es and briefl y highlight 
some promising preclinical developments.
4.1.3 Diﬀ usion Imaging
By incorporati ng diﬀ usion-sensiti zing gradients in a T2-weighted spin echo sequence, 
diﬀ usion-weighted MRI enables quanti fying the microscopic mobility of water in 
biological ti ssues [4,5]. Images are acquired at multi ple diﬀ usion sensiti viti es, allowing 
the calculati on of the apparent diﬀ usion coeﬃ  cient (ADC, in μm2/s) in each image 
element. In general, the cellular proliferati on associated with cancer growth results in 
restricted water mobility (low ADC), while apoptosis and necrosis caused by anti cancer 
therapy results in increased water mobility and thus in increased ADC values [6]. 
Historically, the applicati on of diﬀ usion-weighted MRI in gastrointesti nal cancer has 
been limited due to physiological organ moti lity. Several authors have examined its use 
in rectal cancer, esophageal cancer, and gastrointesti nal stromal tumors (table 4.1). 
Although the reported fi ndings are not enti rely consistent, taken together these studies 
suggest that pretreatment ADC values and the extent of ADC changes during therapy 
may serve as imaging biomarkers of response.
TABLE 4.1. Clinical results of diﬀ usion-weighted MRI in gastrointesti nal cancer
4.1.4 Perfusion Imaging
Since an adequate blood supply is a prerequisite for developing tumors, perfusion 
imaging may be used to diﬀ erenti ate tumors, assess response to therapy, and aid in 
prognosti cati on. Dynamic contrast-enhanced (DCE) MRI has been applied to the study 
of tumor perfusion. DCE-MRI encompasses the dynamic study of ti ssue enhancement 
over ti me aft er intravascular injecti on of a paramagneti c contrast agent (CA) [7]. The 
acquired images provide insight into tumor ti ssue properti es such as blood volume, 
perfusion, and vascular permeability, all of which have been shown to represent 
adequate markers of therapy response [8]. The images acquired may be processed to 
generate semiquanti tati ve (heuristi c) parameters such as area under the curve, ti me 
to peak enhancement, peak intensity, and CA washout rate. Alternati vely, when ti ssue 
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enhancement is combined with simultaneous measurement of CA concentrati on in a 
feeding vessel, pharmacokineti c compartmental modeling becomes possible, which 
yields parametric maps of parameters such as the endothelial transfer constant Ktrans 
[9]. The physiological interpretati on of the calculated parameters criti cally depends 
on the properti es of the CA [10]. When using a small molecule such as gadopentetate 
dimeglumine, extravasati on is ‘perfusion limited’ and mainly refl ects ti ssue perfusion, 
while the use of larger (preclinical) molecules, which do not readily diﬀ use across the 
endothelial lining, allows probing vessel permeability (fi g. 4.1). Table 4.2 lists clinical 
trials in digesti ve cancer using DCE-MRI, all of which have shown that a decrease in CA 
exchange between the vascular and the tumor intersti ti al compartment represents a 
valid biomarker of therapy response. Since the imaging endpoints of a DCE study refl ect 
blood supply in the fi rst place, this technique is ideally suited to study the eﬀ ects of 
anti angiogenic therapy in early-phase clinical trials [11].
TABLE 4.2. Clinical results with DCE-MRI in cancer pati ents
FIGURE 4.1. Example of kineti c modeling based on DCE-MRI. Serial imaging was performed (500 images, temporal 
resoluti on 1.1 s) aft er intravenous injecti on of the macromolecular contrast agent gadomelitol (P792). Parametric map 
of microvascular permeability before and 1 week aft er 5 × 5 Gy of radiotherapy in a rat colorectal tumor implanted in 
the hind leg. The arrow points to vessel used as the arterial input functi on. PS = Permeability surface product; RT = 
radiotherapy.
Using similar kineti c modeling methods, dynamic CT may provide insight into tumor 
perfusion [12]. DCE-CT has been used to monitor the eﬀ ects of anti cancer therapy in 
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lung cancer, rectal cancer, and hepatocellular carcinoma [13,14]. An att racti ve perfusion 
imaging modality is DCE ultrasound using intravenous injecti on of gas ‘microbubbles’ 
surrounded by a polymer shell [15,16]. Obviously, ultrasound-based technology is 
cheap, portable, and minimally invasive. Contrast-enhanced ultrasound has been 
used to predict response in liver, renal, and stromal tumors [17,18]. In additi on to the 
diagnosti c informati on gained by DCE-ultrasound, the combinati on of microbubbles 
carrying a drug payload and focused ultrasound bursts allow targeted drug delivery 
under ultrasound guidance [19,20]. 
4.1.5 Functi onal Lymph Node Imaging
Nodal spread is one of the most important prognosti c variables in solid cancer, and 
nodal status may signifi cantly impact the therapeuti c strategy as well as the pati ent’s 
prognosis. Since morphological criteria have proven insuﬃ  ciently accurate in the 
detecti on of nodal cancer spread, functi onal imaging techniques that would facilitate 
nodal staging are under scruti ny.
4.1.5.1 ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE
Nodal involvement represents one of the most powerful prognosti cators in 
digesti ve cancer, and considerable eﬀ orts have been invested in techniques allowing 
accurate detecti on of lymph node spread. Aft er intravenous injecti on, ultrasmall 
superparamagneti c iron oxide (USPIO) will be taken up by nodal ti ssue, which will darken 
uniformly and homogeneously on T2- and T2*- weighted MRI. In rectal cancer, several 
authors have att empted to diagnose mesorectal nodal involvement. Koh et al. [21] 
compared nodal enhancement patt erns aft er USPIO injecti on with histological analysis 
and found that eccentric and uniform high signal intensity were observed in lymph 
nodes that contained metastases larger than 1 mm in diameter. The same authors found 
that compared to standard MRI, USPIO-enhanced imaging improved specifi city (93 vs. 
75%), although sensiti vity was similar (65%) when compared to histological analysis 
[22]. Beets et al. [23] examined the accuracy of USPIO-enhanced MRI in nodal staging 
of rectal cancer, and found sensiti vity, specifi city, PPV, and NPV of 97, 94, 66, and 99%, 
respecti vely, aft er node-by-node analysis. Unfortunately, the CA used in these studies 
(ferumoxtran-10, Sinerem, Combidex) never received FDA approval and producti on was 
disconti nued several years ago. 
4.1.5.2 GADOLINIUM-BASED BLOOD POOL AGENTS
Using large CAs with a prolonged plasma half-life facilitates measurement of neovascular 
permeability as well as lymphangiography and nodal staging. Many of these compounds 
are in preclinical development, but at present only MS-325 (gadofosveset), a gadolinium 
chelate that is chemically modifi ed causing it to bind strongly but reversibly to plasma 
albumin, is available for clinical use [24]. Lambregts et al. [25 ] reported on the use 
of gadofosveset-enhanced MRI for nodal staging in rectal cancer. When comparing it 
to histology as the standard, they found that sensiti vity and specifi city improved from 
76 and 82% to 80 and 97%, respecti vely, when using gadofosveset (p < 0.001). Other 
macromolecular CAs composed of albumin, polylysine, polysaccharides, poly(ethylene 
glycol), copolymers of cystamine and cysti ne with GD-DTPA, and dendriti c structures 
based on polyamidoamine and polylysine (Gadomers) seem very promising, but are 
presently unavailable for clinical use [26].
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4.1.6 Metabolic Imaging
The cornerstone of imaging tumor metabolism is PET using radiolabeled glucose. The 
use of glucose-based PET imaging is based on the Warburg eﬀ ect, i.e. the phenomenon 
that under aerobic conditi ons, tumor ti ssues metabolize approximately tenfold more 
glucose to lactate in a given ti me than normal ti ssues, notwithstanding preserved 
mitochondrial respirati on [27]. With the excepti on of prostate cancer, the uptake of 
18F-fl uorodeoxyglucose (FDG) is increased in most cancer types and correlates with the 
proliferati on and number of malignant cells [28]. Since changes in metabolic acti vity 
are an early manifestati on of a drug’s anti cancer eﬀ ect, there is considerable interest in 
the use of FDG-PET to measure tumor response. One of the drawbacks associated with 
FDG-PET is the variability in methods to measure FDG uptake, which renders comparison 
between studies diﬃ  cult. Tracer uptake is usually measured semiquanti tati vely 
by calculati ng the standardized uptake value, defi ned as the tumor radiotracer 
concentrati on (in MBq/ml) × body weight (in kg) divided by the injected acti vity (in 
MBq). Alternati vely, kineti c modeling (Patlak plot) may be used to derive the metabolic 
rate for glucose using measurements of the ti me course of radioacti vity in ti ssue and 
in serial arterial blood samples [29]. A recent systemati c review of the accuracy of 
FDG-PET in the predicti on of response to neoadjuvant therapy in esophageal cancer 
showed a pooled sensiti vity of 67% and specifi city of 68% [30]. There was signifi cant 
heterogeneity between included studies, which led the author to conclude that the 
results of FDG-PET should not be used to guide therapy in this pati ent populati on. 
In rectal cancer pati ents treated with neoadjuvant CRT, several small studies have 
demonstrated that FDG-PET uptake predicts the pathological response of the tumor 
[31,32,33]. On the other hand, FDG-PET was shown to be insuﬃ  ciently accurate in 
predicti ng nodal involvement [34].
4.1.7 Hypoxia Imaging
Tissue oxygenati on has been recognized as a central microenvironmental parameter in 
solid tumors for at least 100 years [35]. Areas of varying degrees of hypoxia (defi ned 
as O2 parti al pressure <2.5 mm Hg) are present in most tumors as a consequence of 
limited oxygen diﬀ usion, increased uti lizati on by vessel-proximal cells, and perfusion 
defi ciencies resulti ng from a structurally and functi onally abnormal microvascular 
bed. Hypoxia represents an adverse predicti ve and prognosti c factor, and has been 
implicated in mechanisms as diverse as chemoresistance, radioresistance, angiogenesis, 
vasculogenesis, invasiveness, metastasis, and genomic instability [36]. Several PET 
tracers have been designed for hypoxia imaging [37]. These include the 2-nitroimidazole 
derivati ves 18F-fl uoromisonidazole and 18F-azomycin arabinoside, and 64Cu-methyl-
thiosemicarbazone [38,39,40]. In the absence of molecular oxygen, the 2-nitroimidazole 
compounds are reduced to a highly reacti ve hydroxylamine, which att aches to cellular 
proteins. In head and neck cancer, cervical cancer, and NSCLC, hypoxia PET imaging was 
successfully used to predict response to radiati on or chemoradiati on [41,42]. Dietz et 
al. [43] reported a pilot study using Cu-64-ATSM in rectal cancer pati ents undergoing 
neoadjuvant CRT. They found that a higher tumor ti ssue uptake correlated with worse 
overall and progression free survival. In esophageal cancer pati ents, Yue et al. [44] used 
hypoxia PET imaging with 18F-fl uoroerythronitroimidazole. They found that tracer uptake 
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predicted response to CRT, while a high standardized uptake value was associated with 
poor clinical response.
4.1.8 Proliferati on Imaging
Cellular proliferati on is one of the hallmarks of cancer. 18F-3’-fl uoro-3’deoxythymidine 
(FLT)-PET is incorporated by proliferati ng cells in the pyrimidine salvage pathway during 
the S-phase. The tracer is then phosphorylated by thymidine kinase 1, aft er which 
it accumulates in the cells [45]. In preclinical models, however, tracer avidity was 
signifi cantly inversely correlated with tumor thymidine level and, as a consequence, did 
not always refl ect tumor cell proliferati on [46]. Several clinical studies have aimed to 
use FLT-PET to monitor the response to anti proliferati ve therapy. In breast cancer, FLT-
PET enabled early response predicti on, i.e. aft er one course of chemotherapy [47,48]. 
Similarly, FLT avidity changes refl ected early therapy response in head and neck cancer 
pati ents, whereas discriminati on between malignant and reacti ve lymph nodes turned 
out to be impossible due to due to reacti ve B-lymphocyte proliferati on [49,50]. Wieder 
et al. [51] used sequenti al FLT-PET before and aft er neoadjuvant CRT in rectal cancer 
pati ents. Although a signifi cant decrease in standardized uptake value was observed, 
the degree of change in FLT uptake did not correlate with histological tumor regression. 
Along the same line, Muijs et al. [52] compared CT and FLT-PET in the primary staging of 
rectal cancer and found that compared to CT, FLT-PET performed poorly in delineati on 
of the tumor as well as in malignant node detecti on. A comparison of FDG-PET with FLT-
PET in colorectal cancer pati ents was reported by Yamamato et al. [53]. They found that 
FLT uptake was signifi cantly lower than FDG uptake, and that neither imaging modality 
correlated with the Ki67 proliferati on index. More favorable results were noted in gastric 
cancer pati ents. Herrmann et al. [97] compared FLT-PET with FDG-PET and found FLT 
uptake in all 45 pati ents, whereas 14 gastric tumors were not FDG avid.
4.1.9 Apoptosis Imaging
Inducti on of apoptosis is assumed to be the most important mechanism by which 
anti cancer drugs exert their eﬀ ect. One of the discriminati ng features of the apoptoti c 
cell is the rapid redistributi on of phosphati dylserine from the inner to the outer layer 
of the plasma membrane. Phosphati dylserine-binding agents therefore represent 
att racti ve targets for apoptosis imaging. The fi rst radiolabeled tracer with a nanomolar 
aﬃ  nity for membrane-bound phosphati dylserine was 99mTc-annexin V, the acti vity of 
which is imaged using SPECT. Kartachova et al. [54] used sequenti al annexin V imaging in 
lung cancer pati ents treated with plati num-based chemotherapy, and found a signifi cant 
correlati on between annexin V uptake and treatment response. Similar results were 
obtained by Rott ey et al. [55], who showed that sequenti al annexin V scinti graphy using 
a 25% change threshold allowed discriminati on of nonresponders with 94% accuracy 
aft er 3 days of chemotherapy initi ati on in solid tumor pati ents (fi g. 4.2). Compared with 
SPECT, the use of PET oﬀ ers the advantages of higher count rate, quanti tati ve imaging, 
and improved resoluti on. Eﬀ orts have therefore been invested in the synthesis of 
annexin V-based PET tracers. Examples in preclinical development include labeling of 
annexin V with gallium-68 or N-succinimidyl 4- [18F] fl uorobenzoate, and labeling of the 
annexin V-128 with N- [4- [(4- [18F] fl uorobenzylidene)aminooxy] butyl] maleimide ([F-
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18], FBABM) [56,57,58]. Other apoptosis tracer targets include synaptotagmin, caspase 
inhibitors, and hydrophobic cati ons. Recently, Hoglund et al. [59] reported on a study 
in healthy volunteers with 18F-labeled 2-(5-fl uoropentyl)-2-methyl malonic acid [(18)
F-ML-10], a PET apoptosis tracer. In additi on to a favorable pharmacokineti c and safety 
profi le, the authors observed tracer binding to apoptoti c cells in testi cular ti ssue, where 
these occur in normal circumstances.
 
FIGURE 4.2. Example of sequenti al 99mTc-hydrazinonicoti namide-annexin V imaging for predicti ng response to 
chemotherapy. A signifi cant increase in tracer uptake is noted over ti me in a primary breast tumor (arrows). Reproduced 
with permission from Rott ey et al. [55]. 
Another feature of the apoptoti c process is the sudden halt in protein synthesis, including 
that of choline and choline-containing molecules. Decreases in choline synthesis may 
be detected using 1H magneti c resonance spectroscopy. Thus, several authors have 
demonstrated that reducti on of tumor choline content represents a valid biomarker 
of chemotherapy response in breast cancer pati ents [60,61]. In prostate cancer, the 
maximal choline + creati ne to citrate rati o and choline to creati ne rati o as measured 
by magneti c resonance spectroscopy were shown to separate low-grade from higher-
grade tumors [62]. An exciti ng development is the use of hyperpolarizati on techniques 
to dramati cally (more than 10,000-fold) increase the sensiti vity of magneti c resonance 
spectroscopy tracers based on stable isotopes such as 13C and 15N, which hold signifi cant 
promise in probing the biochemical pathways associated with cancer [63].
4.1.10 Opti cal Imaging
Opti cal imaging is a rapidly emerging fi eld, with widespread applicati ons ranging from 
clinical diagnosis to molecular biology. In the clinic, the endoscope has served as an opti cal 
imaging tool since the 17th century. Compared to cross-secti onal imaging modaliti es, 
endoscopy can provide real-ti me images with high spati al resoluti on, enabling the 
detecti on of very small anatomic changes, and oﬀ ers immediate interventi on, such as 
biopsy of neoplasti c lesions. With the introducti on of fl uorescent CA, the functi ons of 
traditi onal endoscopy are further extended. Chromoendoscopy involves the applicati on 
of spraying a fl uorescent CA onto the mucosa using a spray catheter passed through a 
standard endoscope. It has been shown that in large human studies, chromoendoscopy 
improves earlier diagnosis of adenomas and colorectal cancers [64]. Another study 
showed that chromoendoscopy permits more accurate diagnosis of the extent and 
the severity of neoplasti c lesions [65]. Despite these positi ve preliminary results, some 
studies have shown that the fl uorescent CA used during chromoendoscopy (methylene 
blue) might induce DNA damage, and consequently accelerate carcinogenesis [66]. Such 
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risks need to be carefully balanced against the possible benefi ts of improved earlier 
disease detecti on.
Indocyanine green has been heavily tested for adverse reacti ons and is a fl uorescent CA 
that rapidly binds to blood proteins aft er intravenous injecti on [67]. It can be used to 
provide informati on of the vasculature of the digesti ve tract that cannot be obtained by 
conventi onal endoscopy [68]. Kimura et al. [69] evaluated the eﬀ ecti veness of fl uorescent 
endoscopy for the preoperati ve evaluati on of tumor invasion in pati ents with superfi cial 
gastric tumors, and concluded that submucosal invasion has a higher correlati on with 
fl uorescence than macroscopic morphology of tumors and histopathologic tumor 
diﬀ erenti ati on. Indocyanine green has also been used for the detecti on of metastases to 
a senti nel lymph node in melanoma, gastric cancer, and lung cancer pati ents [70,71,72]. 
Recently, more sophisti cated opti cal probes have been developed that target or interact 
with biological processes on a molecular level aft er being exogenously delivered. Most 
of these probes are completi ng preclinical validati on in mouse models and the design 
of such probes involves the att achment of a fl uorophore to a targeti ng moiety, such as a 
pepti de, an anti body or a fragment of an anti body, small molecules, and nanoparti cles 
[73,74,75]. Another class of opti cal agents changes their fl uorescent properti es aft er 
target interacti on, rather than targeti ng surface receptors and proteins. 
These smart probes are initi ally opti cally silent and become fl uorescent as a result 
of enzymati c cleavage of fl uorophores from a delivery backbone in the presence of 
protease [76]. This technique has been proven to be very successful in combinati on 
with endoscopic applicati ons [77].
4.1.11 Multi modality Imaging
In previous paragraphs, various structural, functi onal, and molecular imaging 
technologies were introduced. Table 4.3 lists some performance parameters of diﬀ erent 
imaging modaliti es available. Since the properti es of anatomical (CT, MRI) and functi onal 
(PET, SPECT) imaging modaliti es are rather complementary, integrati ng the informati on 
obtained from these modaliti es into one platf orm takes ‘the best of both worlds’. 
Multi modality platf orms – such as PET/CT, SPECT/CT, PET/MRI, and SPECT/MRI – with 
each modality having its unique strengths and limitati ons play an increasingly important 
role in the diagnosis and staging of human disease [78]. The major technological 
advances in PET instrumentati on before the advent of CT, excellently documented by 
Muehllehner and Karp [79], culminated in the introducti on of a hybrid PET/CT system 
in 1998 [80]. This was undeniably a very important step to use PET as a viable clinical 
tool, with PET/CT being the most widely used multi modality platf orm today. Among 
multi modality platf orms, PET/MRI may ulti mately provide the greatest yield of scienti fi c 
informati on, combining the impressive technological developments of PET with 
the excellent anatomic resoluti on and soft -ti ssue contrast provided by MRI [81]. An 
important advantage of PET/MRI over the other multi modality platf orms is that PET 
and MRI data can be acquired simultaneously, rather than sequenti ally. A clinical PET/
MRI device that allows the simultaneous acquisiti on of whole-body PET and MRI images 
became commercially available in 2011 (Biograph™ mMR, Siemens).
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TABLE 4.3. Performance parameters of diﬀ erent imaging modaliti es
Preclinically, there is a trend to combine opti cal imaging and radionuclide (PET/SPECT) 
imaging. Besides the large diﬀ erence in the energy of the emitt ed photons (1–2 eV vs. 105 
eV), opti cal and radionuclide imaging are quite similar. Both are based on the detecti on 
of photons emitt ed from a source inside the body, and both use highly sensiti ve photon 
detectors positi oned outside the body to detect the signals. In additi on, for both the 
measured signal is directly proporti onal to the biological process under examinati on. Due 
to these similariti es, and because opti cal imaging suﬀ ers from poor ti ssue penetrati on, 
it is natural to consider the development of combined opti cal/radionuclide imaging 
devices and dual-modality probes that can be used in a similar fashion to produce 
opti cal signals when used in small animals, or yield PET/SPECT signals to facilitate the 
translati on to the clinic. In the clinic, these dual-modality probes can provide, next to 
radionuclide images, additi onal informati on when combined with surgical techniques, 
where the excited ti ssue can be visualized opti cally [82].
4.1.12 Conclusion
Cancer imaging has evolved from a mere morphological investi gati on to a physiology-
based in-depth analysis of tumor biology. In the era of personalized medicine, functi onal 
and molecular imaging will allow us to tailor treatment according to predicti ve and 
prognosti c imaging-based biomarkers. Standardizati on and clinical validati on of novel 
imaging modaliti es should be a priority in clinical cancer therapy and incorporated in 
interventi onal cancer trials.
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Chapter 4.2: Molecular imaging of tumour associated angiogenesis using a
novel MRI contrast agent targeti ng AlphaVBeta3 integrin
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Synopsis
Molecular MRI enhances tumour associated angiogenesis in a colorectal xenograft  
model, using a monogadolinated tracer targeti ng αvβ3 integrin.
4.2.1 Abstract
Background: The recent introducti on of biological anti cancer therapy has renewed 
the interest in functi onal imaging of tumour associated angiogenesis (TAA) as a tool 
to monitor early therapy response. The present study evaluated imaging of TAA using 
P1227, a novel small molecular MRI probe targeti ng αvβ3 integrin.
Methods: HT29 human colorectal cancers were grown in athymic mice. Dynamic MR 
imaging was performed using a 3D VIBE sequence up to 110 minutes aft er injecti on of 
P1227 or gadolinium-tetraazacyclododecane tetraaceti c acid (Gd-DOTA). Specifi city was 
assessed by using P1227 one hour aft er IV administrati on of the αvβ3 inhibitor cilengiti de. 
Regions of interest were drawn encompassing the tumour rim and normal muscle. 
Imaging data were compared with microvessel density (MVD) and αvβ3 expression.
Results: Using P1227, specifi c enhancement of the angiogenic tumour rim, but not of 
normal muscle was observed whereas Gd-DOTA enhanced tumour and normal muscle. 
Aft er administering cilengiti de, enhancement with P1227, but not with DOTA was 
signifi cantly suppressed during the fi rst 20 minutes. When using P1227, a signifi cant 
correlati on was observed between normalized enhancement of the tumour rim and 
immunohistochemical αvβ3 integrin expression.
Conclusions: molecular MR imaging using a small monogadolinated tracer targeti ng αvβ3 
integrin and moderate magneti c fi eld strength holds promise in assessing colorectal TAA.
4.2.2 Introducti on
Early assessment of response to cytotoxic therapy is an area of intense investi gati on. 
Indeed, the ability to demonstrate acti vity early in the course of therapy not only allows 
to predict an individual pati ent’s prognosis but also to tailor the therapeuti c strategy 
by ti mely disconti nuati on of inacti ve regimens. Moreover, early imaging of tumour 
response is a valuable tool in preclinical and early phase clinical drug development.
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Changes in the physical dimension of a solid tumour, which underly the traditi onal 
RECIST criteria, oft en occur late in the course of therapy1. Also, as exemplifi ed by 
molecular therapy of gastrointesti nal stromal tumours, signifi cant tumour response 
can occur without any accompanying change in tumour dimension². Early iconographic 
assessment of tumour response is not (only) based upon morphological, but on functi onal 
properti es of the neoplasti c ti ssue. Research for other valuable early imaging biomarkers 
is currently ongoing. Since the introducti on of agents targeti ng tumour angiogenesis, 
increasing eﬀ orts have been invested in functi onal imaging of the neoplasti c vascular 
bed. Importantly, it has been shown that the earliest functi onal change in response to 
anti -angiogenic therapy is ‘microvessel normalizati on’, id est, the return from a grossly 
distorted anatomy and functi on to more physiological microvascular properti es³. 
One of the hallmarks of this process is a decrease in microvascular permeability. We 
recently showed that dynamic contrast enhanced (DCE) magneti c resonance imaging 
incorporati ng mathemati cal modelling allows to quanti fy these early changes in 
microvessel permeability as well as tumour perfusion4.
Although of interest, these parameters remain indirect esti mators of tumour 
angiogenesis. Direct, specifi c imaging requires probes directed against moieti es 
expressed on the proliferati ng endothelial cell (EC) surface. A potenti al targets is αvβ3 
integrin, which is selecti vely expressed on acti vated EC during migrati on through the 
basement membrane in the angiogenic process6-7. This protein is not upregulated on 
quiescent EC8. Here, we studied a novel αvβ3 integrin directed molecular MRI tracer 
(P1227) as a tool to visualise tumour angiogenesis in a colorectal xenograft  model.
4.2.3 Methods
ANIMALS AND TUMOUR MODEL
Colorectal cancer xenograft s (HT29) were subcutaneously grown in the hind leg of nude 
mice (athymic nu/nu, Harlan, The Netherlands). Animals were housed separately in 
plasti c cages with free access to tap water and standard pellet food. When tumours 
reached a size of 0.2-0.3 cm³ (aft er 8-10 days), MRI imaging was performed. The protocol 
was approved by the local Animal Research insti tuti onal review board.
MR IMAGING PROTOCOL
Dynamic MR image acquisiti on was performed on a MAGNETOM Symphony 1.5 T clinical 
scanner (Siemens Healthcare, Brussels, Belgium) using a wrist coil (diameter 10 cm). 
Imaging was performed using a T1 weighted 3D VIBE sequence (FOV 180x80, matrix size 
384x384,voxel dimension 0.5x0.5x2 mm, TR/TE 6.78/2.78 ms, fl ip angle 12°, 60 slices, 
total durati on per scan 9 min 25 sec). Images were acquired at baseline (before contrast 
injecti on) and at regular intervals up to 225 minutes post injecti on. At each ti me point 
60 images were acquired.
Signal intensity was measured in blinded, manually drawn regions of interest (ROIs) 
encompassing the tumour rim (outer third of the tumour volume) and normal ti ssue 
(contralateral paravertebral muscle). Normalized Enhancement Rati o (NER) was 
calculated as the rati o of enhancement in the tumour rim over enhancement in normal 
muscle ti ssue.
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MR CONTRAST AGENT
The contrast agent (P1227, Guerbet Research, Paris, France) is a tetraazacyclododecane 
tetraaceti c acid (DOTA) – gadolinium (Gd) chelate linked to a cyclic RGD pepti de 
(MW= 1297 Da). The purifi ed protein used to determine binding IC50 of P1227 is
vitronecti n. The molecular weight of Gd-DOTA is 560 Da. The r1 relaxiviti es of P1227 and 
Gd-DOTA in plasma at 37°C and 1.5 T are 8.3 mM-1s-1 and 3.8 mM-1s-1 respecti vely. The 
binding IC50 of P1227 as tested with ELISA on purifi ed protein is 3 nM.
Four experimental groups were studied. In the fi rst group, imaging was performed before 
and aft er injecti on of P1227 (dose 50 μmol Gd/kg) (N=15), while in the second (control) 
group mice underwent imaging before and aft er injecti on of Gd-DOTA (Dotarem®, 
Guerbet, Paris, France; dose 100 μmol Gd/kg) (N=9). The choice of doubling the Gd-
DOTA dose was based on the much higher relaxivity of P1227. In the third and fourth 
group imaging with P1227 (N=9) or Gd-DOTA (N=6), respecti vely, was performed one 
hour aft er IV administrati on of the αvβ3 inhibitor cilengiti de (dose 1800 mg/m², Merck 
KGaA, Darmstadt, Germany). All products were injected as a rapid IV bolus through the 
tail vein.
IMMUNOHISTOCHEMISTRY
On the day aft er MR imaging, tumours were excised and all mice were sacrifi ced using 
cervical dislocati on. Half of the tumour ti ssue was fi xed in 10% formalin, embedded in 
paraﬃ  n, and 4 μm thick secti ons were cut and mounted for immunohistochemistry. 
Factor VIII (von Willebrand factor, FVIII) immunostaining was used to visualise tumour 
microvessels and calculate microvessel density (MVD). FVIII staining procedure was 
adapted from Debergh et al.9. The other half of the tumour was snap frozen in liquid 
nitrogen, cut in 5 μm thick secti ons and mounted for immunohistochemistry with mouse 
anti -human integrin αvβ3 (US Biological – Immunosource), similar to the procedure of 
Schnell et al.
WESTERN BLOT ANALYSIS
Quanti fi cati on of αvβ3 integrin protein expression using Western Blot, was described by 
Schnell et al.10. Briefl y, snap frozen tumour ti ssues were lysed in radioimmunoprecipitati on 
assay buﬀ er by sonicati on. Total protein content was determined with the Bio-Rad DC 
protein assay kit (Bio-Rad, Nazareth, Belgium). Fift y micrograms of protein per lane was 
mixed with LDS sample buﬀ er (NuPAGE, Invitrogen, Merelbeke, Belgium). The proteins 
were denatured by heati ng at 70°C for 10 minutes, seperated with 170 V over 1 hour 
in running buﬀ er (NuPAGE® MES, Invitrogen). Aft er that, proteins were transferred to 
a nitrocellulose membrane (GE Healthcare, Buckinghamshire, United Kingdom) by 
a semidry blotti  ng technique. Next, membranes were blocked over 1 hour at room 
temperature. The primary anti bodies against integrin subunits (polyclonal rabbit anti -
integrin αv subunit AB1930; diluti on 1:5000 and polyclonal rabbit anti -integrin β3 subunit 
AB1932; diluti on 1:2000; Chemicon, Millipore, MA, USA) were incubated overnight at 
4°C. Bound anti bodies were labeled using a secondary anti body coupled to alkaline 
phosphatase (1:2000 goat anti -rabbit immunoglobulin/AP) for 1 hour. Visualisati on was 
performed using chromogen nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP/NBT substrate kit, Invitrogen). Blots were subsequently stripped and 
reprobed with monoclonal anti body against β-tubulin (Abcam, United Kingdom; diluti on 
064871 thesis 16x24 niet split.indd   77 2/09/14   07:10
78
1:5000) as an internal control for protein loading. All blots were digiti zed by scanning, 
mean intensity of each diﬀ erent chain was measured with NIH ImageJ soft ware and the 
the overall relati ve intensity of the diﬀ erent chains of interest was calculated (mean 
intensity of chain of interest/mean intensity of tubulin).
STATISTICAL ANALYSIS
Data are expressed as mean ± SEM or median (interquarti le range). Diﬀ erences were 
analyzed using the student t or Mann-Whitney rank sum test where appropriate. 
Correlati ons between histology data and imaging parameters were assessed with 
Spearman rank correlati on. Stati sti cal analysis was performed with SigmaStat 11.0 
(Systat Soft ware, Richmond, USA). Results were considered stati sti cally signifi cant when 
the probability of a type I error was ≤ 5%.
4.2.4 Results
Signal enhancement in tumour and normal muscle aft er injecti on of P1227 versus Gd-
DOTA
Typical enhancement patt erns are illustrated in fi gure 4.3. It may be appreciated that, as 
illustrated by the signal intensity histograms, P1227 specifi cally enhanced the angiogenic 
tumour rim while Gd-DOTA was more homogeneously distributed towards the center of 
the tumour.
FIGURE 4.3 Enhancement patt ern observed following administrati on of P1227 (upper left ) or Gd-DOTA (upper right). The 
histograms (lower row) show frequency of signal intensiti es in the enti re tumour (black), central (core) region (blue), and 
tumour rim (red).
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FIGURE 4.4 Normalized enhanced rati o (NER) over ti me in regions of interest encompassing the tumour rim and enti re 
tumour following administrati on of P1227 (circles) or Gd-DOTA (triangles). NER, Normalized Enhanced Rati o, bars = s.e..
FIGURE 4.5 Normalized enhancement rati o (NER) of the tumour rim over ti me following administrati on of DOTA or P1227 
with or without pretreatment with cilengiti de (open circles). NER, Normalized Enhanced Rati o, bars = s.e.
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Quanti tati ve evaluati on of the signal intensity changes observed in the tumour rim, 
enti re tumour, and normal muscle is provided in fi gure 4.4, where NER are depicted. 
NER in the enti re tumour appears to be lower than NER in the tumour rim at each ti me 
point. When using P1227, signifi cant enhancement of signal intensity was observed of 
the tumour rim (569 ± 15 versus 472 ± 21, P=0.004, t test) but not of normal muscle. 
However, when using Gd-DOTA, signifi cant enhancement of SI was noted in both tumour 
ti ssue and normal ti ssue (614 ± 24 versus 430 ± 17 in muscle ti ssue, P<0.001, t test). For 
both contrast agents, a peak in normalized enhancement was observed aft er 5 minutes. 
When using P1227 normalized enhancement aft er 225 minutes did return to baseline. 
When using Gd-DOTA, however, normalized enhancement at 225 minutes remained 
signifi cantly elevated compared to baseline (precontrast) level (1,261 ± 0,0818 versus 
1,098 ± 0,122; P=0.035, t-test).
Signal enhancement in the tumour rim with and without pretreatment with cilengiti de
To verify whether P1227 binds the target integrin in a specifi c way, the inhibitor 
cilengiti de was administered one hour before imaging with P1227 (n=9). The results, 
expressed as the rati o of enhancement in the tumour rim over enhancement in normal 
ti ssue, are illustrated in fi gure 4.5. Administrati on of cilengiti de before P1227 resulted 
in a signifi cantly lower normalized contrast enhancement of the tumour rim during the 
fi rst 20 minutes (P=0.027, U test). Between 35 and 60 minutes NER was sti ll higher in the 
P1227 group, but without showing stati sti cally signifi cant diﬀ erences compared to the 
cilengiti de pretreated group. Aft er 80-90 minutes, however, no diﬀ erences in SI were 
observed between both groups. When DOTA was used, however, pretreatment with 
cilengiti de did not aﬀ ect tumour rim enhancement.
Immunohistochemistry and Western blot
Microvessel density (vWF staining) in all tumours, expressed as the vascular area 
fracti on, was signifi cantly higher in the tumour rim compared to the enti re tumour 
(11.25% (8.7-16.7) versus 8.4% (4.6-12.2), P<0.001, U test). Also, the percentage of 
αvβ3 integrin expressing endothelium was 12.8% (10.9-16.9) in the tumour rim versus 
11.2% (7.9-14.6) in the enti re tumour (P=0.002, U test; fi gure 4.6, panel B and C). The 
results of Western blotti  ng confi rmed that protein expression of the alpha v and beta 3 
subunit was signifi cantly higher in the vascular tumour rim (fi gure 4.6, panel A and D). 
Three diﬀ erent molecular masses can be found in alpha v subunits (at 137 kDa and to a 
much lesser extent at 27 and 25 kDa) and in beta 3 subunits (between 90-100 kDa and 
degradati on products at 64 and 52 kDa)10.
Correlati on of MR imaging parameters with histology data
Correlati on data are summarised in Table 4.4. When using Gd-DOTA, no correlati on was 
observed between the NER in the tumour rim and either αvβ3 integrin expression or 
MVD. However, when using P1227, a stati sti cally signifi cant positi ve correlati on was 
observed between αvβ3 integrin expression and the NER at 35, 50, and 65 minutes post 
contrast injecti on.
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  5 min 20 min 35 min 50 min 65 min 80 min
αvβ3 integrin DOTA 0.7 0.92 0.88 0.36 0.72 0.06
 P1227 0.43 0.39 0.019 0.0092 0.046 0.35
MVD DOTA 0.52 0.63 0.99 0.9 0.59 0.86
 P1227 0.44 0.69 0.57 0.49 0.67 0.47
TABLE 4.4 Correlati on between histology and imaging parameters (normalized enhancement rati o of the
tumour rim).
m, minutes ; numbers indicate P values from Pearson correlati on analysis.
4.2.5 Discussion
We have studied the feasibility to probe tumour angiogenesis using a novel MR contrast 
agent targeti ng αvβ3 integrin.
The integrins are a group of evoluti onary conserved heterodimeric cell surface receptors 
which are essenti al in cell-cell and cell-matrix interacti ons11.
Some subtypes are highly overexpressed on cancer cells, e.g. αvβ3, αvβ5, α5β1 (which 
play important role in mediati ng tumour angiogenesis), or αvβ6 and α6β4 (with pivotal 
functi ons in cell migrati on and hence, metastasis)12,13. These interesti ng capaciti es of 
certain integrins, and the high level of expression on some tumour types, makes them 
ideal candidates for targeted therapy and imaging studies.
More specifi cally, integrinαvβ3 is not only overexpressed on some tumour cell types 
(lung cancer, ovarian cancer, breast cancer, glioblastoma multi forme,…), but also on 
FIGURE 4.6 Protein expression measured by Western Blot of alphav chains and beta3 chains (A and D); bars = s.d.,
* P ≤ 0.05. Representati ve αvβ3 integrin immunohistology of the tumour rim (B) and tumour center (C). Scale bar =
100 μm.
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most tumour endothelial cells and not on normal blood vessels13. Targeti ng tumour 
angiogenesis and reducing side-eﬀ ects on normal ti ssue is of major interest in the 
evoluti ng research of cancer treatment. In this way, site-specifi c delivery of drugs and 
imaging can show early eﬀ ecti veness of therapy, and diminish chemo-resistance. The 
recogniti on sequence of the αvβ3 integrin is the RGD (Arg-Gly-Asp) pepti de on the β3 
domain, and its most abundant ligands are components of the extracellular matrix, 
f.i. fi bronecti n, vitronecti n, and fi brinogen14. Its expression on endothelial cells is 
sti mulated by angiogenic growth factors such as bFGF, TNFα and IL8 and is upregulated 
not only in neoplasti c ti ssue but also during wound healing and infl ammati on8. The 
HT29 colorectal cancer cell line used in the present experiment was shown to express 
integrins αvβ5, αvβ6, and αvβ815,16. The expression of human integrin αvβ3 is negligible 
on HT29 tumour cells, but tumours express murine integrin αvβ3, which is present on 
newborn tumour vasculature in this mouse model. Recently, several studies proved with 
the HT29 model the relati on between RGD-based radiotracer uptake in tumours and the 
expression levels of both human integrin αvβ3 and murine integrin αvβ317,18. In our study, 
the HT29 model allows us to focus directly on tumour associated angiogenesis via this 
novel αvβ3 integrin specifi c molecular tracer (P1227).
The uti lity of MRI based molecular imaging is hampered by its low sensiti vity to visualize 
epitopes which are oft en present in the nanomolar range. Therefore, eﬀ orts have been 
directed towards the combinati on of the target-specifi c molecule with a large (super)
paramagneti c payload. Several authors have used RGD-coupled liposomes containing 
Gd-DTPA to visualise tumour angiogenesis19,20. Others have used RGD-labeled ultra-
small superparamagneti c iron oxide nanoparti cles (USPIO) and T2 weighted imaging21-23. 
Several disadvantages are associated with the use of these large carriers. First, since 
they are exclusively limited to the vascular compartment, binding sites on the tumour 
cells and extracellular matrix will be out of reach24. Second, endocytosis of the Gd-
labeled liposomes may lead to ‘quenching’ of the MRI signal. Third, concerns have risen 
regarding the safety and biological side eﬀ ects of USPIOs in early clinical trials, although 
these were usually mild and reversible25. Finally, the pharmacokineti c properti es of 
nano-sized tracers, including a plasma half live of several hours and retenti on by the 
reti culo-endothelial system bett er suit therapeuti c than diagnosti c purposes.
Here, we report for the fi rst ti me the use of a low molecular weight tracer (1297 Da, 
diameter of 1-2 nm) consisti ng of a routi nely used monogadolinated CA linked to a RGD 
pepti de as a tool to image tumour associated angiogenesis. The results demonstrate 
that, compared to non-targeted DOTA (MW = 558 Da), P1227 bett er discriminates 
angiogenic tumour ti ssue from normal muscle. Gd-DOTA pools immediately in the 
blood, as both SI in tumour rim and muscle are high, whereas P1227 does not change 
SI in muscle. Furthermore, aspecifi c accumulati on of Gd-DOTA in the well vascularised 
oedemateous tumour ti ssue leads to persistent high NERs, even aft er 225 minutes. At 
this point, SI in normal muscle ti ssue did return to baseline, indicati ng that the high SI of 
tumour rim is due to extravasated Gd-DOTA tracer. This may be explained by the higher 
molecular weight of P1227, which limits diﬀ usion across normal and leaking tumoural 
microvessel linings. Retenti on of the tracer due to specifi c binding to the target integrin 
was demonstrated by the near complete disappearance of P1227-induced tumour 
enhancement aft er pretreatment with cilengiti de. Cilengiti de is a known inhibitor of 
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the integrins αvβ3, αvβ5, and α5β1, but blocking the other integrins is not interfering with 
the imaging result of HT29 tumours as P1227 was designed to have only specifi city for 
the RGD-sequence on the β3 domain of the αvβ3 integrin. Compared to nanoparti cle 
imaging, the peak in signal enhancement aft er injecti ng P1227 occurs much earlier (aft er 
5 minutes). Sipkins and coworkers26, who used an αvβ3 targeti ng anti body conjugated 
paramagneti c liposome to image tumour angiogenesis in a rabbit model, noted specifi c 
enhancement of angiogenic areas aft er a ti me window of 24 hours. Similarly, Winter and 
coworkers19, who used an integrin directed nanoparti cle with a size of approximately 
70 nm, observed steadily increasing signal intensity in the experimental tumour model 
unti l the completi on of the imaging aft er 120 minutes. The relati vely low accumulati on 
of the tracer in the present model may be explained by the smaller size of the agent 
and by low internalisati on by HT29 cells, as demonstrated in vitro by Bloch et al.27. This 
HT29 tumour cell line, is known to express litt le amounts of integrin αvβ315. Radiolabeled 
cyclic RGD pepti des specifi cally accumulate in αvβ3 expressing tumours by higher probe 
internalizati on, and increases when cyclic pepti des are polymerized28-29.
The specifi city of the novel tracer for αvβ3 integrin was further demonstrated by the 
correlati on between immunohistochemical staining and the observed MRI enhancement. 
No stati sti cally signifi cant correlati on was noted with MVD, yet the the factor VIII staining 
method used does not allow to disti nguish proliferati ng, acti ve endothelial cells from 
resti ng microvessel linings.
Several limitati ons apply to the interpretati on of the present results. First, although 
immunohistochemistry of integrin chain expression can be regarded as a valid surrogate 
marker of acti ve angiogenesis, no golden standard is available at present. Correlati on of 
MR imaging with in vivo microscopic imaging of fl uorescently labelled tracers may hold 
promise in this regard30.
Second, although expression of αvβ3 integrin is generally low in healthy ti ssue, it is known 
to be expressed by several other cell types (epithelial cells, fi broblasts, smooth muscle 
cells) and to be implicated in other conditi ons including arterial stenosis31. An additi onal 
tumour model with diﬀ erent integrin expression level to demonstrate the ability of the 
probe, would be interesti ng to discriminate ti ssues with diﬀ erent expression levels. 
Finally, it may be envisaged that compared to nanoparti cles with a high Gd payload, the 
sensiti vity of the current tracer for detecti ng small lesions will be limited.
In conclusion, we have shown that molecular MR imaging using a small monogadolinated 
tracer targeti ng αvβ3 integrin holds promise in safely and non-invasively assessing 
colorectal tumour angiogenesis. Future work will include assessment of anti angiogenic 
therapy eﬀ ects using this novel tracer.
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CHAPTER 5: General discussion and Conclusion
5.1 General discussion
Cancer incidence and mortality will most likely increase dramati cally in the next decades, 
due to the growth and aging of the global populati on. Cancer preventi on, early cancer 
diagnosis and pati ent-tailored treatment are important challenges for the near future, 
to improve survival rates and quality of life, and to avoid unnecessary side-eﬀ ects 
for pati ents and reduce costs for the society. Currently, most pati ents are treated in 
a multi modality way, including surgery, chemotherapy, radiati on and immunotherapy. 
Despite many eﬀ orts the underlying mechanisms of cancer development, cancer 
behaviour, response or resistance to treatment, metastasis, are not fully elucidated. 
The aim of our work was to unravel some basic aspects of targeti ng angiogenesis in 
tumours, as treatment opti on or imaging modality, and in this way to contribute to 
clinical soluti ons for the enigma of cancer.
Hypercoagulability is typically seen in cancer pati ents, due to the pro-coagulant eﬀ ects 
of cancer cells (releasing TF) or to eﬀ ects of chemotherapy, indwelling catheters, surgery, 
and immobility. For this reason, administrati on of LMWH is sti ll the gold standard in the 
VTE prophylaxis of cancer pati ents [1]. LMWHs have been tested in various randomized 
controlled trials and clearly show a superiority to other anti coagulant treatments, due 
to predictable pharmacokineti c properti es with rapid onset of acti on, fast clearance and 
easy dosage [2].
Coagulati on can fuel tumour progression by forming tumour cell emboli with 
platelets and leukocytes, and seeding into the microcirculati on. An essenti al role in 
the coagulati on cascade is performed by the acti vati on of thrombin, which promotes 
tumour cell adhesion and release of VEGF and bFGF from mast cells [3]. Results from 
several clinical studies suggested that heparin therapy might improve survival in cancer 
pati ents [4-6], independently of the anti coagulant eﬀ ect. Heparins of various molecular 
weight, including LMWH, UF, and chemically modifi ed non-anti coagulant heparins, 
have been shown to inhibit tumour growth and metastasis formati on in animal 
studies [7-8]. The mechanisms through which LMWHs exert anti cancer eﬀ ects remain 
incompletely understood, but we highlighted the early anti angiogenic eﬀ ect on tumour 
microcirculatory events using in vivo microscopy in an immunocompetent animal model.
In chapter 3.1, we studied tumoural angiogenesis via in vivo fl uorescence microscopy in 
a dorsal skinfold chamber model using contrast agent that is tagged with a fl uorescent 
marker (FITC–labelled dextran). This procedure in a hamster model is described in 
detail by Endrich et al. [9] and Menger et al. [10], and proved to be an excellent tool to 
visualize early microvascular changes by calculati ng stati c (microvessel length per area, 
number of microvessels per high-power fi eld, vascular area fracti on, and microvessel 
diameter) and dynamic (centreline red blood cell velocity and volumetric blood fl ow) 
parameters in a non-invasive, longitudinal way. Together with immunohistochemical 
data, Factor VIII (von Willebrand factor) immunostaining to calculate microvessel density 
(MVD) and fractal dimension, and α-smooth muscle acti n (αSMA) staining to identi fy 
pericytes and calculate the pericyte coverage index (PCI), tumour microenvironment 
can be assessed. Other studies performed use cell culture experiments or other in vivo 
angiogenesis assays, such as the mouse cremaster muscle or rat mesenteric window 
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model, which allow to observe the microcirculati on only once aft er therapy [11,12]. 
An orthotopic tumour model was studied (amelanoti c melanoma) and an 
adenocarcinoma (pancreati c tumour). Our results suggest that nadroparin exerts an 
anti angiogenic eﬀ ect in vivo, as evidenced by a signifi cantly lower vascular area fracti on 
and MVD when compared with control animals. Moreover, nadroparin-treated tumours 
showed signs of microvessel normalizati on, including a smaller increase in diameter, a 
higher PCI, and less vessel tortuosity (smaller fractal dimension). Vessel normalizati on 
is a well-characterised early phenotypic eﬀ ect of anti angiogenic therapy [13]. The 
diﬀ erence in vessel diameter and tortuosity may explain the decrease in vascular area 
fracti on over ti me in nadroparin-treated animals despite the fact that both vessel length 
and vessel number did not change appreciably over ti me in this group. We extrapolated 
the study of tumour microvascular normalizati on using IVM to human cancer cells in a 
nude mouse model.
In chapter 3.2, we examined the eﬀ ect of commercially available and widely used LMWHs 
nadroparin and enoxaparin, on human colorectal tumour in a mouse model. The results 
show that both nadroparin and enoxaparin have early anti angiogenic properti es, as seen 
in IVM experimental data with signifi cantly lower vascular area fracti on, microvessel 
density, length and number of microvessels when compared with control animals.
Underlying mechanisms of the anti angiogenic properti es of LMWHs, may include 
inhibiti on of binding of angiogenic growth factors to their endothelial receptors [14]. 
In a Matrigel assay, endothelial cell proliferati on and tube formati on was inhibited 
maximally by LMWH with a chain length of >8 polysaccharides and a molecular weight of 
6 kDa while no inhibiti on was observed with UFH, tetrasaccharide, pentasaccharide, or 
octasaccharide [15]. Also in vitro, heparin fragments of less than 18 saccharides reduce 
the acti vity of VEGF [16] and fragments of less than 10 saccharide residues inhibits the 
acti vity of bFGF [17]. In vivo, the same eﬀ ect of small heparin fracti ons on bFGF acti vity 
has been described [18,19]. Similar fi ndings were reported by Norrby [11], who showed 
that 2.5–5kDa heparin fragments maximally suppressed VEGF-induced angiogenesis in 
a rat mesenteric window assay.
So, the anti angiogenic potenti al of LMWHs seems to be depending on the molecular 
weight and number of saccharide units. In our experiment, we compared the in vivo 
eﬀ ect of commercially available nadroparin (4.3 kDa) and enoxaparin (4.5 kDa) on 
tumour angiogenensis with similar molecular weights. Small diﬀ erences in results can 
be explained by diﬀ erent polysaccharide mixtures, but evidently, both bFGF and VEGF 
can be targeted in the anti angiogenic process, which is a plausible explanati on of the 
positi ve short term results on tumour-associated angiogenesis. It is known that in 
pati ents receiving bevacizumab, a monoclonal anti -VEGF anti body, therapy resistance 
or disease progression can be expected due to “escape pathways”, with upregulati on 
of PlGF, PDGF, and bFGF [20]. Targeti ng multi ple escape pathways is a tool to overcome 
adaptati on of the tumour to treatment.
Another criti cal event in the process of cancer invasion, metastasis or tumoural 
angiogenesis is the degradati on of various components of the ECM, including collagen, 
laminin, fi bronecti n and HSPGs. This can be accomplished by heparanase, secreted by 
cancer cells. Heparanase expression is rare in normal ti ssue, but is evident in many 
human tumours where it signifi cantly increases both the angiogenic and metastati c 
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potenti al of cancer cells [21]. In vitro, LMWH with a mean weight of 4.5kDa inhibited 
99% of heparanase acti vity [22]. Thus, nadroparin- and enoxaparin induced blocking of 
heparanase could possibly make the ECM less permissive for tumoural neovasculature. 
Indeed, structural alterati ons of the fi brin matrix induced by LMWH reduced the invasion 
of capillary-forming endothelial cells [23].
Our studies also describe a stati sti cally signifi cant increase in PCI, thus a bett er maturati on 
of microvessels compared to tumoural vessels due to treatment with enoxaparin or 
nadroparin. An angiogenic signal (f.i. VEGF or bFGF) coming from tumour cells, will 
detach pericytes from the vessel wall and make endothelial cells loosen their juncti ons; 
as a consequence this pathological vessel dilates. VEGF increases the permeability of 
the endothelial cell layer, causing plasma proteins to extravasate and to increase the 
intersti ti al pressure [24]. We also observed a normalized diameter aft er treatment 
with nadroparin or enoxoparin in tumoural microvessels. In diﬀ erent reports, tumour 
vessel normalizati on appeared to be able to open new therapeuti c opportuniti es to 
slow down tumour invasiveness and disseminati on, and increase tumour responses to 
chemotherapeuti cs and radiotherapy than anti -angiogenic therapy alone [25] due to 
bett er perfusion of tumours and delivery of drugs.
Searching for early biomarkers of tumour response, diﬀ erent aspects of tumour 
physiology, rather than morphology, can be measured in a non-invasive way through 
various types of imaging modaliti es, as discussed in the overview given in chapter 4.1. 
A frequently used method of functi onal cancer imaging uses tumour metabolism of 
glucose: 18F-fl uorodeoxyglucose (FDG) PET or a multi modality scan combining PET and 
CT. Cancer cells oft en take up more glucose than normal cells, due to both increased 
and anaerobic metabolism (also known as the ‘Warburg eﬀ ect’) [26]. In the predicti on 
of reponse to neoadjuvant therapy, e.g. in esophageal cancer, this method proved to 
have a sensiti vity of 67% and specifi city of 68% [27], so FDG-PET should not be used to 
guide therapy in this clinical setti  ng. More promising for this applicati on are other types 
of PET tracers currently designed for tumour cell proliferati on and apostosis, but wide 
clinical testi ng needs to be done yet. Also, for tumour hypoxia imaging [28], Yue et al. 
[29] used hypoxia PET imaging with 18F-fl uoroerythronitroimidazole. They found that 
tracer uptake predicted response to CRT, while a high standardized uptake value was 
associated with poor clinical response.
New developments in functi onal and molecular imaging have drawn att enti on on MR. 
Diﬀ usion-weighted MRI enables quanti fying the cellular proliferati on index of cancer 
cells, as cancer growth results in restricted diﬀ usion, while apoptosis and necrosis 
caused by anti cancer therapy results in increased diﬀ usion values [30]. Secondly, tumour 
perfusion-weighted imaging techniques are currently validated and include dynamic 
contrast enhanced (DCE)-MRI, but also DCE-CT or ultrasound, allowing the dynamic 
study of ti ssue enhancement over ti me aft er intravascular injecti on of a contrast 
agent (CA) [31]. The acquired images provide insight into tumour ti ssue properti es 
such as blood volume, perfusion, and vascular permeability, all of which have been 
shown to represent adequate surrogate markers of therapy response [32]. Moreover, 
in DCE-MRI, when ti ssue enhancement is combined with simultaneous measurement 
of CA concentrati on in a feeding vessel, pharmacokineti c compartmental modeling is 
possible, which yields e.g. the endothelial transfer constant Ktrans [33], a parameter for 
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vascular permeability. Early response of tumour ti ssue to anti -angiogenic therapy, will 
lead to decreasing (normalizing) permeability of microvasculature. In chapter 4.2, we 
studied the feasibility of using a tumour angiogenesis specifi c probe for molecular MR 
imaging. We examined a human colorectal cancer cell line in a mouse model, known to 
express murine integrin αvβ3 on newborn tumour vasculature, but not on the tumour 
cells themselves [34-37]. The recogniti on sequence of the αvβ3 integrin is the RGD (Arg-
Gly-Asp) pepti de on the β3 domain [38], and the novel contrast agent tested in our 
experiment (P1227) consists of a routi nely used monogadolinated CA linked to this RGD 
pepti de as a tool to image tumour associated angiogenesis.
The uti lity of MRI based molecular imaging is hindered by its low sensiti vity to 
visualize nanomolar epitopes. This is why target-specifi c molecules were developed 
in combinati on with a large (super)paramagneti c payload. Several authors have used 
RGD-coupled liposomes containing Gd-DTPA to visualize tumour angiogenesis [39,40]. 
Others have used RGD-labeled ultra-small superparamagneti c iron oxide nanoparti cles 
(USPIO) and T2 weighted imaging [41-43], but several disadvantages are associated 
with the use of these parti cles. First, binding sites on the tumour cells and extracellular 
matrix can not be reached since these large carriers are limited to the intravascular 
compartment [44]. Also, concerns have risen regarding the safety and biological side 
eﬀ ects of USPIOs in early clinical trials, although these were usually mild and reversible 
[45]. And fi nally, the pharmacokineti c properti es of nano-sized tracers, including a 
plasma half live of several hours and retenti on by the reti culo-endothelial system bett er 
suit therapeuti c than diagnosti c purposes. Our results with the new low molecular 
weight tracer P1227 demonstrate that, compared to non-targeted DOTA, P1227 bett er 
discriminates angiogenic tumour ti ssue from normal muscle. Furthermore, aspecifi c 
accumulati on of Gd-DOTA in the well vascularised oedemateous tumour ti ssue leads 
to persistently elevated signal intensiti es, even aft er several hours, due to contrast 
extravasati on. Retenti on of the P1227 tracer due to specifi c binding to the target integrin 
was demonstrated by the near complete disappearance of P1227-induced tumour 
enhancement aft er pretreatment with cilengiti de (a known inhibitor of the integrins 
αvβ3, αvβ5, and α5β5). The specifi city of the novel tracer for αvβ3 integrin was further 
demonstrated by the correlati on between αvβ3 integrin immunohistochemical staining 
and the observed MRI enhancement.
5.2 Conclusion
Taken together, LMWHs act on several fronts of anti cancer therapy, through 
anti coagulant-dependent mechanisms and direct anti tumour eﬀ ects. Although LMWHs 
signifi cantly improved overall survival in cancer pati ents without venous thrombosis, 
the use of anti coagulants as anti neoplasti c therapy cannot be recommended unti l 
additi onal randomized controlled trials confi rm these results [46]. The use of novel oral 
anti coagulants is not currently recommended for pati ents with malignancy and VTE, 
but trials are ongoing. In general, chariness is advised concerning the risk of bleeding 
during treatment with heparins. Therefore, non-anti coagulant low molecular weight 
heparins were developed for treati ng cancer pati ents because these products can be 
dosed higher, and can be administered in pati ents with bleeding risk. In this way, the 
anti tumour or anti metastati c properti es can be exploited completely [47]. Preclinically, 
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these non-anti coagulant LMWHs seem to be promising neoadjuvant therapies, as they 
disti nctly increased tumour necrosis and enhanced chemoresponse in mouse breast, 
lung and pancreati c cancer models [48,49].
Developing new strategies in the war on cancer is crucial, but disrupti ng the cancer’s 
capabiliti es is complex: multi targeti ng of the hallmarks of cancer is necessary [50,51], 
avoiding cumulati ve toxiciti es, and assuring correct ti ming and dosing of therapies to 
prevent adapti ve or evasive resistance of the tumour [52-54]. Despite all eﬀ orts, vascular 
mimicry and mosaic vessel formati on allow tumours to escape from anti angiogenic 
strategies. Other partners in the tumour ecosystem will have to be targeted too, such as 
carcinoma-associated fi broblasts, endothelial cells and immune cells (Fig.5.1) [55-58]. 
Another sobering issue is the great economic cost of cancer treatment, which poses 
serious cost-benefi t dilemmas for pati ents and governments. Experimental work to 
deepen the knowledge of the mechanisms of angiogenesis is nonetheless necessary for 
treatment strategies in other fi elds of medicine, such as endometriosis, ocular diseases, 
cirrhosis, ischemic cardiac diseases, and ti ssue engineering [59].
 
FIGURE 5.1 Tumour/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. (Adapted from Gomes 
et al., 2013 [57])
Searching performant biomarkers for evaluati ng anti cancer therapy is another important 
topic of further experimental work. New preclinical and clinical studies will prove the 
eﬃ  cacy of new imaging probes targeti ng tumour angiogenesis. In this way, site-specifi c 
imaging and delivery of drugs can show early eﬀ ecti veness of therapy, diminish costs 
and chemo-resistance, and reduce side-eﬀ ects on normal ti ssue, which is of major 
interest in the evolving research of cancer treatment. The development of these new 
imaging tools and contrast agents will be challenging, concerning selecti vity for tumour 
ti ssue and avoidance of background noise, ti ming of administrati on of the product, 
bioavailability and safety for the pati ent [60].
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Our group is currently studying the eﬀ ects of VEGF-inhibitors on microvasculature in 
a peritoneal carcinomatosis model. Normalizati on of the tumour vasculature could 
lead to locally reduced IFP, and an increased diﬀ usion/penetrati on of intraperitoneally 
delivered cytotoxic drugs.
Future work of our team will include the study of vascular normalizati on and treatment 
synergism in the combinati on of anti angiogenics. We will uti lise in vivo fl uorescence 
microscopy to study capillary permeability and its normalizati on aft er anti angiogenic 
regimens using fl uorescently labelled tracers, and using tumour cells that express green 
fl uorescent protein. Anti angiogenic regimens include radiotherapy (SARRP) with or 
without a pan-VEGF receptor tyrosine kinase inhibitor. Furthermore, comparison with 
concomitant in vivo tumour models (without dorsal skinfold chambers) are necessary 
to avoid some limitati ons of the IVM set up, and to have a detailed view on microvessel 
normalizati on with measurements of neovascular permeability (Ktrans in DCE-MRI), 
plasma and intersti ti al oncoti c pressure (IFP), oxygenati on (hyperspectral imaging fi lter) 
and erythrocyte fl ow (laser Doppler) in the tumour region.
Ulti mately, these IVM fi ndings can than be used as a gold standard for correlati on with 
functi onal and molecular imaging of tumour neoangiogenesis and eﬀ ects of multi modal 
treatment strategies.
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During multi plicati on of neoplasti c cells, all necessary nutrients and oxygen are delivered 
by passive diﬀ usion, which is suﬃ  cient for distances up to 100-200 μm. Aft er reaching 
a criti cal tumour mass, the formati on of new blood vessels (angiogenesis) is needed to 
feed the tumour. Inhibiti on of tumour-associated angiogenesis (TAA) or normalizati on 
of the pathological microvasculature is a logic next step in treati ng cancer. To develop 
anti angiogenic molecules, and to adequately follow pati ents during treatment strategies, 
it is crucial to fi nd early anti -angiogenic molecular eﬀ ects and validated biomarkers.
First, we investi gated tumour associated angiogenesis and the anti -angiogenic eﬀ ects 
of therapy using in vivo microscopy (IVM), a non-invasive method which allows detailed 
repeti ti ve examinati on of microvasculature. The anti tumour eﬀ ect of nadroparin, a 
frequently used LMWH, is thought to rely on vascular normalizati on (chapter 3.1). We 
studied tumoural angiogenesis and the eﬀ ects of nadroparin via in vivo fl uorescence 
microscopy in a dorsal skinfold chamber model in hamsters using contrast agent that 
is tagged with a fl uorescent marker (FITC–labelled dextran). Morphological (length of 
microvessels, number of vessels per area, diameter, vascular area fracti on), dynamic (red 
blood cell velocity and volumetric blood fl ow), and immunohistochemical data (pericyte 
coverage index, fractal dimension, and microvesssel density) were gathered to assess 
tumour microenvironment and the eﬀ ects of nadroparin therapy on AMel-3 (hamster 
melanoma) and HaP-T1 (hamster pancreati c carcinoma) tumours. In this tumour model, 
nadroparin revealed to have anti -angiogenic eﬀ ects, leading to a normalized tumour 
microvasculature, including a smaller increase in diameter, a higher PCI (maturati on), 
and less vessel tortuosity (smaller fractal dimension). In chapter 3.2, we examined 
the eﬀ ects of nadroparin and enoxaparin, frequently used LMWHs, using IVM and the 
dorsal skinfold chamber model, but this ti me we used a human colorectal cancer model 
in athymic mice. Our results suggest that both nadroparin as enoxaparin exert an anti -
angiogenic eﬀ ect in human colorectal carcinoma, as evidenced by a signifi cantly lower 
vascular area fracti on, microvessel density, length and number of microvessels when 
compared with control animals.
The validati on of reliable biomarkers of TAA is an important challenge for the future, 
enabling an early and eﬀ ecti ve detecti on of anti -angiogenic eﬀ ects. Diﬀ erent aspects 
of tumour physiology, rather than morphology, can be measured in a non-invasive 
way through various types of imaging modaliti es, as discussed in the overview given 
in chapter 4.1. One imaging technique, molecular imaging, was studied in chapter 
4.2, using a new contrast agent targeti ng integrin αvβ3 (P1227), expressed in tumoural 
endothelial cells and not in normal endothelium. Colorectal cancer xenograft s (HT29) 
were subcutaneously grown in the hind leg of nude mice and MRI was performed 
before contrast agent administrati on and at several ti me intervals aft er injecti on of 
P1227 or Gd-DOTA, an aspecifi c blood pool CA. ROIs were drawn and the normalized 
enhancement rati o (NER) was calculated in the tumour. Aft er quanti fi cati on of tumour 
associated angiogenesis via P1227, images were taken aft er injecti on of cilengiti de, a 
specifi c inhibitor of αvβ3mediated cell adhesion. Using P1227, specifi c enhancement of 
the angiogenic tumour rim, but not of normal muscle was observed whereas Gd-DOTA 
enhanced tumour and normal muscle. Aft er administering cilengiti de, enhancement 
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with P1227, but not with DOTA was signifi cantly suppressed during the fi rst 20 minutes. 
When using P1227, a signifi cant correlati on was observed between normalized 
enhancement of the tumour rim and immunohistochemical αvβ3 integrin expression. 
We showed that molecular MR imaging using a small monogadolinated tracer targeti ng 
αvβ3 integrin holds promise in assessing colorectal TAA.
Future work of our group will include a complete study of the tumour microenvironment 
and vessel normalizati on aft er anti angiogenic regiments using in vivo fl uorescent 
microscopy, measurements of laser Doppler erythrocyte fl ow, plasma and intersti ti al 
oncoti c pressure, neovascular permeability (Ktrans in DCE-MRI) and oxygenati on in the 
tumour region.
Ulti mately, these IVM fi ndings can than be used as a gold standard for correlati on with 
functi onal and molecular imaging of tumour neoangiogenesis and eﬀ ects of multi modal 
treatment strategies.
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Tijdens neoplasti sche celdeling worden zuurstof en nutriënten aangebracht via passieve 
diﬀ usie, die toereikend is over afstanden tot 100-200 μm. Na het bereiken van een 
kriti sch tumorvolume is vorming van nieuwe bloedvaten (angiogenese) nodig om de 
tumor te voeden. Het inhiberen van tumorale angiogenese of de normalisati e van 
deze pathologische bloedvaten is dan ook een logische stap in de behandeling van 
kanker. Zowel voor de ontwikkeling van anti angiogene moleculen als voor het adequaat 
opvolgen van kankerpati ënten is het van groot belang vroegti jdige anti -angiogene 
moleculaire eﬀ ecten en gevalideerde biomerkers op te sporen.
Wij onderzochten in hoofdstuk 3 tumorale angiogenese en de anti -angiogene 
eﬀ ecten van therapie door middel van in vivo microscopie (IVM), een niet-invasieve 
methode waarbij gedetailleerd repeti ti ef onderzoek van microvasculatuur mogelijk 
is. Het anti -tumorale eﬀ ect van nadroparine, een frequent gebruikt laag moleculair 
gewichts heparine (LMWH), zou berusten op het bevorderen van tumorale vasculaire 
normalisati e (hoofdstuk 3.1). We bestudeerden tumorale angiogenese en de eﬀ ecten 
van nadroparine via in vivo fl uorescenti e microscopie in een dorsal skinfold chamber 
model in hamsters, waarbij een contraststof werd aangewend die gemerkt is met een 
fl uorescente merker (FITC– dextraan). Morfologische (lengte van microvasculatuur, 
aantal bloedvaten, diameter, vasculaire fracti e), dynamische (rode bloedcel snelheid 
en debiet), en immunohistochemische gegevens (pericyten coverage index, fractale 
dimensie, en bloedvatendensiteit) werden verzameld om de tumorale micro-omgeving 
en de eﬀ ecten van behandeling met nadroparine te beoordelen op AMel-3 (hamster 
melanoma) en HaP-T1 (hamster pancreascarcinoom) tumoren. In deze tumor modellen 
bleek nadroparine anti -angiogene eﬀ ecten te hebben met een genormalizeerde tumor 
microvasculatuur tot gevolg, waaronder een beperktere toename in bloedvatdiameter, 
een hogere PCI (maturati e) en minder tortueuze bloedvaten (lagere fractale dimensie). 
In hoofdstuk 3.2 onderzochten we opnieuw de eﬀ ecten van zowel nadroparine als 
enoxaparine, courant gebruikte LMWHs, via IVM en het dorsal skinfold chamber model, 
maar ditmaal werd een humaan colorectaal carcinoommodel gebruikt in athymische 
muizen. Onze resultaten suggereerden dat zowel nadroparine als enoxaparine 
anti angiogene eﬀ ecten teweegbrengen ook in een humaan colorectaal carcinoom, zoals 
gestaafd werd door een signifi cant lagere vasculaire fracti e, bloedvatendensiteit, lengte 
en aantal microvaten na vergelijking met de controle dieren.
Het valideren van betrouwbare biomerkers van tumorale angiogenese is een belangrijke 
uitdaging voor de toekomst om snel en eﬀ ecti ef eﬀ ecten van anti -angiogene therapie 
op te sporen. Verschillende aspecten van tumor fysiologie, in plaats van tumor 
morfologie, kunnen op een niet-invasieve manier worden gemeten via verschillende 
types beeldvorming, zoals werd besproken in hoofdstuk 4.1. Eén ervan, moleculaire 
beeldvorming, werd door ons onderzocht (hoofdstuk 4.2) door middel van een nieuwe 
contrastof gericht tegen het αvβ3 integrine (P1227), dat tot expressie wordt gebracht 
in tumoraal endotheel en nauwelijks in normaal endotheel. Hierbij werd in naakte 
muizen een humane HT29 colorectale tumor in de fl ank geïnduceerd en vervolgens MR 
beeldvorming uitgevoerd vóór contrastt oediening en op geregelde ti jdsti ppen na injecti e 
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van P1227 of Gd-DOTA, een aspecifi eke contraststof. Aan de hand van deze beelden 
werd de normalized enhancement rati o (NER) berekend in de tumor. Na quanti fi ceren 
van tumorale angiogenese aan de hand van P1227, werd ook beeldvorming uitgevoerd 
na toediening van cilengiti de, dat specifi ek αvβ3-gemedieerde celbinding blokkeert. Na 
toediening van P1227 kon specifi eke aankleuring van de angiogene tumorrand maar 
niet van normaal spierweefsel aangetoond worden, terwijl Gd-DOTA zowel tumor als 
spierweefsel deed aankleuren. Na toedienen van cilengiti de werd de contrastaankleuring 
van P1227 signifi cant onderdrukt ti jdens de eerste 20 minuten; bij Gd-DOTA werd dit 
verschil niet waargenomen. Tenslott e werd ook een signifi cante correlati e gevonden 
in de P1227 groep, tussen NER van de tumorrand en immunohistochemische αvβ3 
integrine expressie. Hierbij kunnen we besluiten dat moleculaire MRI via een kleine 
monogadolinium tracer die op αvβ3 integrine bindt, een beloft evolle techniek is in het 
evalueren van colorectale tumorale angiogenese.
Toekomsti g werk van onze groep zal zich focussen op een complete studie van de 
tumorale micro-omgeving en bloedvatnormalisati e na anti angiogene therapie via 
in vivo fl uorescente microscopie, meti ngen via laser Doppler doorbloeding, plasma 
en intersti ti ële oncoti sche druk, neovasculaire permeabiliteit (Ktrans in DCE-MRI) en 
oxygenati e in de tumorregio.
Uiteindelijk zullen deze resultaten van het IVM onderzoek gebruikt kunnen worden als 
gouden standaard voor correlati e met functi onele en moleculaire beeldvorming van 
tumorale angiogenese en de eﬀ ecten van multi modale behandelingsstrategieën.
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